EBOS Group Limited
Annual Report 2014

Plain-text annual report

Annual Report 2014 Well Placed Financial statements Twelve months to 30 June 2014 Directors’ Responsibility Statement Independent Auditor’s Report Income Statement Statement of Comprehensive Income Balance Sheet Statement of Changes in Equity Cash Flow Statement Notes to the Financial Statements Additional Stock Exchange Information Board of Directors Corporate Governance Statement Directory 2 3 4 4 5 6 8 9 45 46 48 54 EBOS Annual Report 2014 | 1 DIRECTORS’ RESPONSIBILITY STATEMENT The Directors of EBOS Group Limited are pleased to present to shareholders the financial statements for EBOS Group and its controlled entities (together the “Group”) for the year to 30 June 2014. The Directors are responsible for presenting financial statements in accordance with New Zealand law and generally accepted accounting practice, which give a true and fair view of the financial position of the Company and the Group as at 30 June 2014 and the results of their operations and cash flows for the year ended on that date. The Directors consider the financial statements of the Company and the Group have been prepared using accounting policies which have been consistently applied and supported by reasonable judgements and estimates and that all relevant financial reporting and accounting standards have been followed. The Directors believe that proper accounting records have been kept which enable with reasonable accuracy, the determination of the financial position of the Company and Group and facilitate compliance of the financial statements with the Financial Reporting Act 1993. The Directors consider that they have taken adequate steps to safeguard the assets of the Company and the Group, and to prevent and detect fraud and other irregularities. Internal control procedures are also considered to be sufficient to provide a reasonable assurance as to the integrity and reliability of the financial statements. The Financial Statements are signed on behalf of the Board by: Rick Christie Chairman 26 August 2014 Mark Waller Director EBOS Annual Report 2014 INDEPENDENT AUDITOR’S REPORT TO THE SHAREHOLDERS OF EBOS GROUP LIMITED Report on the Financial Statements We have audited the financial statements of EBOS Group Limited and group on pages 4 to 44, which comprise the consolidated and separate balance sheets of EBOS Group Limited, as at 30 June 2014, the consolidated and separate income statements, statements of comprehensive income, statements of changes in equity and cash flow statements for the year then ended, and a summary of significant accounting policies and other explanatory information. This report is made solely to the company’s shareholders, as a body, in accordance with Section 205(1) of the Companies Act 1993. Our audit has been undertaken so that we might state to the company’s shareholders those matters we are required to state to them in an auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company’s shareholders as a body, for our audit work, for this report, or for the opinions we have formed. Board of Directors’ Responsibility for the Financial Statements The Board of Directors are responsible for the preparation of financial statements in accordance with generally accepted accounting practice in New Zealand and that give a true and fair view of the matters to which they relate, and for such internal control as the Board of Directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. Auditor’s Responsibilities Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with International Standards on Auditing and International Standards on Auditing (New Zealand). Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement. An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor’s judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation of financial statements that give a true and fair view of the matters to which they relate in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of accounting estimates, as well as the overall presentation of the financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion. Other than in our capacity as auditor, and the provision of information technology services, financial modelling assistance and assurance services for indirect tax compliance, we have no relationship with or interests in EBOS Group Limited or any of its subsidiaries. These services have not impaired our independence as auditors of the Company and Group. Opinion In our opinion, the financial statements on pages 4 to 44: • comply with generally accepted accounting practice in New Zealand; • comply with International Financial Reporting Standards; • give a true and fair view of the financial position of EBOS Group Limited as at 30 June 2014, and their financial performance and cash flows for the year then ended. Report on Other Legal and Regulatory Requirements We also report in accordance with section 16 of the Financial Reporting Act 1993. In relation to our audit of the financial statements for the year ended 30 June 2014: • we have obtained all the information and explanations we have required; and • in our opinion proper accounting records have been kept by EBOS Group Limited as far as appears from our examination of those records. Chartered Accountants 26 August 2014 Christchurch, New Zealand This audit report relates to the financial statements of EBOS Group Limited and group for the year ended 30 June 2014 included on EBOS Group Limited website. EBOS Group Limited is responsible for the maintenance and integrity of the EBOS Group Limited website. We have not been engaged to report on the integrity of EBOS Group Limited website. We accept no responsibility for any changes that may have occurred to the financial statements since they were initially presented on the website. The audit report refers only to the financial statements named above. It does not provide an opinion on any other information which may have been hyperlinked to/from these financial statements. If readers of this report are concerned with the inherent risks arising from electronic data communication they should refer to the published hard copy of the audited financial statements and related audit report dated 26 August 2014 to confirm the information included in the audited financial statements presented on this website. Legislation in New Zealand governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions. EBOS Annual Report 2014 | 3 INCOME STATEMENT For the Financial Year Ended 30 June, 2014 Notes Group 2014 $’000 2013 $’000 Parent 2014 $’000 2013 $’000 Revenue 2 (a) 5,760,053 1,823,169 119,346 111,433 Income from Associates 2 (b) 1,567 585 - - Profit before depreciation, amortisation, finance costs and tax expense Depreciation Amortisation of finite life intangibles Profit before finance costs and tax expense Finance costs Profit before tax expense Tax expense Profit for the year Earnings per share: Basic (cents per share) Diluted (cents per share) 2 (b) 2 (b) 2 (b) 2 (b) 3 178,241 (10,173) (12,410) 155,658 (29,877) 125,781 (33,712) 58,243 (4,922) (1,514) 51,807 (9,593) 42,214 (14,007) 49,023 (539) - 48,484 (5,613) 42,871 (264) 40,558 (552) - 40,006 (5,028) 34,978 (118) 92,069 28,207 42,607 34,860 26 26 62.8 62.8 46.8 46.8 STATEMENT OF COMPREHENSIVE INCOME For the Financial Year Ended 30 June, 2014 Notes Group 2014 $’000 2013 $’000 Parent 2014 $’000 2013 $’000 Profit for the year 92,069 28,207 42,607 34,860 Other comprehensive income Items that may be reclassified subsequently to profit or loss: Cash flow hedges gains/(losses) Related tax expense to cashflow hedges Translation of foreign operations 22 22 22 (2,423) 701 (24,194) 2,773 (359) (6,365) (618) 173 - 1,532 (250) - Total comprehensive income net of tax expense 66,153 24,256 42,162 36,142 Notes to the financial statements are included on pages 9 to 44. EBOS Annual Report 2014 BALANCE SHEET As at 30 June 2014 Notes Current assets Cash and cash equivalents Trade and other receivables Prepayments Inventories Current tax refundable Other financial assets - derivatives Advances to subsidiaries Total current assets Non-current assets Property, plant and equipment Capital work in progress Prepayments Deferred tax assets Goodwill Indefinite life intangibles Finite life intangibles Shares in subsidiaries Investment in associates Total non-current assets Total assets Current liabilities Trade and other payables Finance leases Bank loans Current tax payable Employee benefits Other financial liabilities - derivatives Advances from subsidiaries Deferred purchase consideration Total current liabilities Non-current liabilities Bank loans Trade and other payables Deferred tax liabilities Finance leases Employee benefits Total non-current liabilities Total liabilities Net assets Equity Share capital Foreign currency translation reserve Retained earnings Cash flow hedge reserve Total equity Notes to the financial statements are included on pages 9 to 44. Group 2014 $’000 88,698 699,276 6,748 491,624 83 1,442 - 2013 $’000 198,014 736,429 7,837 558,350 1,628 3,546 - 1,287,871 1,505,804 84,854 20,872 54 36,589 720,875 56,576 77,502 - 24,100 95,131 787 16 34,361 722,158 59,324 95,145 - 19,013 Parent 2014 $’000 4,075 8,217 941 8,912 - 1,337 31,671 55,153 4,764 - - 252 1,728 4,960 - 949,324 - 2013 $’000 89,305 10,399 838 9,146 722 1,816 34,468 146,694 4,668 - - 310 1,728 4,960 - 1,080,686 - 1,021,422 1,025,935 961,028 1,092,352 2,309,293 2,531,739 1,016,181 1,239,046 6 7 8 3 9 10 11 7 3 12 13 14 15 16 18 17, 19 17 3 20 17 24 17 18 3 17, 19 821,391 155 153,334 14,219 28,830 3,404 - - 892,645 1,189 215,675 6,378 25,725 2,872 - 865,000 1,021,333 2,009,484 250,826 9,778 43,407 680 4,230 151,357 8,489 48,365 3,296 5,871 308,921 217,378 6,356 - 4,000 - 2,101 352 29,319 - 42,128 85,500 - 2,279 - - 87,779 9,172 - 4,000 - 5,820 - 29,319 865,000 913,311 87,412 - 2,220 - - 89,632 1,330,254 2,226,862 129,907 1,002,943 979,039 304,877 886,274 236,103 21 22 22 22 861,549 (29,869) 147,085 274 201,288 (5,675) 107,268 1,996 861,549 - 23,978 747 201,288 - 33,623 1,192 979,039 304,877 886,274 236,103 EBOS Annual Report 2014 | 5 STATEMENT OF CHANGES IN EQUITY Share Capital For the Financial Year ended 30 June, 2014 Notes $’000 Foreign Currency Translation Reserve $’000 Retained Earnings Hedge Reserve Total $’000 $’000 $’000 Group Balance at 1 July, 2012 Profit for the year Other comprehensive income for the year, net of tax expense Payment of dividends Dividends re-invested Shares issued under employee share ownership scheme Institutional placement Share issue costs Balance at 30 June, 2013 Balance at 1 July, 2013 Profit for the year Other comprehensive income for the year, net of tax expense Payment of dividends Dividends re-invested Shares issued under rights issue Share issue costs Issue of consideration shares Share issue costs 23 21 21 21 21 23 21 21 21 21 21 107,970 - - - 6,545 250 90,026 (3,503) 201,288 201,288 - - - 20,496 149,119 (7,356) 498,147 (145) 690 - (6,365) - - - - - 100,359 28,207 - (21,298) - - - - (5,675) 107,268 (5,675) - (24,194) - - - - - - 107,268 92,069 - (52,252) - - - - - (418) - 2,414 - - - - - 1,996 1,996 - (1,722) - - - - - - 208,601 28,207 (3,951) (21,298) 6,545 250 90,026 (3,503) 304,877 304,877 92,069 (25,916) (52,252) 20,496 149,119 (7,356) 498,147 (145) Balance at 30 June, 2014 861,549 (29,869) 147,085 274 979,039 Notes to the financial statements are included on pages 9 to 44. EBOS Annual Report 2014 STATEMENT OF CHANGES IN EQUITY continued For the Financial Year ended 30 June, 2014 Notes Share Capital $’000 Retained Earnings $’000 Hedge Reserve $’000 Total $’000 Parent Balance at 1 July, 2012 Profit for the year Other comprehensive income for the year, net of tax expense Payment of dividends Dividends re-invested Shares issued under employee share ownership scheme Institutional placement Share issue costs Balance at 30 June, 2013 Balance at 1 July, 2013 Profit for the year Other comprehensive income for the year, net of tax expense Payment of dividends Dividends re-invested Shares issues under rights issue Share issue costs Issue of consideration shares Share issue costs 107,970 - - - 6,545 250 90,026 (3,503) 20,061 34,860 - (21,298) - - - - 201,288 33,623 201,288 - - - 20,496 149,119 (7,356) 498,147 (145) 33,623 42,607 - (52,252) - - - - - 23 21 21 21 21 23 21 21 21 21 21 (90) - 1,282 - - - - - 1,192 1,192 - (445) - - - - - - 127,941 34,860 1,282 (21,298) 6,545 250 90,026 (3,503) 236,103 236,103 42,607 (445) (52,252) 20,496 149,119 (7,356) 498,147 (145) Balance at 30 June, 2014 861,549 23,978 747 886,274 Notes to the financial statements are included on pages 9 to 44. EBOS Annual Report 2014 | 7 CASH FLOW STATEMENT For the Financial Year ended 30 June, 2014 Notes Cash flows from operating activities Receipts from customers Interest received Dividends received from subsidiaries Payments to suppliers and employees Taxes paid Interest paid Group 2014 $’000 2013 $’000 Parent 2014 $’000 5,732,731 2,819 - (5,561,884) (29,637) (29,877) 1,917,358 1,198 - (1,869,090) (13,458) (9,593) 74,528 1,221 45,775 (75,741) - (5,613) 2013 $’000 68,966 1,388 39,623 (61,062) - (5,028) Net cash inflow from operating activities 25(c) 114,152 26,415 40,170 43,887 Cash flows from investing activities Sale of property, plant & equipment Purchase of property, plant & equipment Payments for capital work in progress Payments for intangible assets Advances to subsidiaries Acquisition of associates Acquisition of subsidiaries Costs associated with acquisition of subsidiaries 1,351 (11,725) (20,115) (3,467) - (3,520) (366,853) - 403 (2,943) (778) (142) - - 49,263 (5,993) - (657) - - 2,797 - (235,491) - 11 (236) - - (7,959) - - (5,993) 16 25(a) Net cash (outflow)/inflow from investing activities (404,329) 39,810 (233,351) (14,177) Cash flows from financing activities Proceeds from issue of shares Proceeds from borrowings Repayment of borrowings Dividends paid to equity holders of parent 162,114 310,327 (233,136) (52,252) 93,318 30,009 (21,474) (21,298) 162,114 93,500 (95,411) (52,252) 93,318 - (19,838) (21,298) 23 Net cash inflow from financing activities 187,053 80,555 107,951 52,182 Net (decrease)/increase in cash held Effect of exchange rate fluctuations on cash held Net cash and cash equivalents at beginning of the year Net cash and cash equivalents at the end of the year Cash and cash equivalents Notes to the financial statements are included on pages 9 to 44. (103,124) (6,192) 198,014 146,780 (1,105) 52,339 88,698 198,014 88,698 198,014 (85,230) - 89,305 4,075 4,075 81,892 - 7,413 89,305 89,305 EBOS Annual Report 2014 NOTES TO THE FINANCIAL STATEMENTS For the Financial Year ended 30 June, 2014 1. SUMMARY OF ACCOUNTING POLICIES 1.1 STATEMENT OF COMPLIANCE EBOS Group Limited (“the Company”) is a profit-oriented company incorporated in New Zealand, registered under the Companies Act 1993 and listed on both the New Zealand and Australian Stock Exchanges. The Company operates in two business segments, being Healthcare and Animal care. Healthcare incorporates the sale of healthcare products in a range of sectors, own brands, retail healthcare, wholesale activities, and logistics. Animal care incorporates the sale of animal care products in a range of sectors, own brands, retail and wholesale activities. The Company is a reporting entity and issuer for the purposes of the Financial Reporting Act 1993 and its financial statements comply with that Act. The financial statements have been prepared in accordance with Generally Accepted Accounting Practice in New Zealand (‘NZ GAAP’). They comply with New Zealand Equivalents to International Financial Reporting Standards (“NZ IFRS”) and other applicable reporting standards as appropriate for profit oriented entities. The Financial Statements comply with International Financial Reporting Standards (“IFRS”). 1.2 BASIS OF PREPARATION The financial statements have been prepared on the basis of historical cost, except for the revaluation of certain financial instruments. Cost is based on the fair value of the consideration given in exchange for assets. Accounting policies are selected and applied in a manner which ensures that the resulting financial information satisfies the concepts of relevance and reliability, thereby ensuring that the substance of the underlying transactions or other events is reported. The accounting policies set out below have been applied in preparing the financial statements for the year ended 30 June, 2014 and the comparative information presented in these financial statements for the year ended 30 June, 2013. The information is presented in thousands of New Zealand dollars. 1.3 CRITICAL JUDGEMENTS IN APPLYING ACCOUNTING POLICIES In the application of NZ IFRS management is required to make judgements, estimates and assumptions about carrying values of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgements. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an on-going basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. Judgements made by management in the application of NZ IFRS that have significant effects on the financial statements and estimates with a significant risk of material adjustments in the next year are disclosed, where applicable, in the relevant notes to the financial statements. Critical judgements made by management principally relate to the identification of intangible assets such as brands and customer relationships separately from goodwill, arising on acquisition of a business or subsidiaries and the recognition of revenue on significant contracts subject to renewal where the receipt of cashflows does not match the services provided. 1.4 KEY SOURCES OF ESTIMATION UNCERTAINTY Key sources of estimation uncertainty relate to assessment of impairment of goodwill and indefinite life intangibles. The Group determines whether goodwill and indefinite life intangibles are impaired at least on an annual basis. This requires an estimation of the recoverable amount of the cash generating units to which the goodwill and indefinite life intangibles are allocated. The assumptions used in this estimation of recoverable amount and the carrying amount of goodwill and indefinite life intangibles are discussed in notes 12 and 13. It is assumed that significant contracts will be rolled over for each period of renewal. An impairment assessment of goodwill has been conducted in the current year. Management have determined that there is no impairment of any of the cash generating units containing goodwill (refer Note 12). Determining the recoverable amounts of goodwill and intangible assets requires the estimation of the effects of uncertain future events at balance date. These estimates involve assumptions about risk assessment to cash flows or discount rates used, future changes in salaries and future changes in price affecting other costs. 1.5 SPECIFIC ACCOUNTING POLICIES The following specific accounting policies have been adopted in the preparation and presentation of the financial statements. a) Basis of Consolidation The consolidated financial statements are prepared by combining the financial statements of all the entities that comprise the Group, being the Company (the Parent entity) and its subsidiaries as defined in NZ IAS-27 ‘Consolidated and Separate Financial Statements’. A list of subsidiaries appears in note 15 to the financial statements. Consistent accounting policies are employed in the preparation and presentation of the consolidated financial statements. Acquisitions of subsidiaries and businesses are accounted for using the acquisition method. The cost of the acquisition is measured at the aggregate of the fair values, at the date of exchange, of assets given, liabilities incurred or assumed, and equity instruments issued by the Group in exchange for control of the acquiree. Acquisition-related costs are recognised in profit or loss as incurred. EBOS Annual Report 2014 | 9 1. SUMMARY OF ACCOUNTING POLICIES continued Where applicable, the cost of acquisition includes any asset or liability resulting from a contingent consideration arrangement, measured at its acquisition date fair value. Subsequent changes in such fair values are adjusted against the cost of acquisition where they qualify as measurement period adjustments. All other subsequent changes in the fair value of contingent consideration classified as an asset or liability are accounted for in accordance with relevant NZ IFRSs. Changes in the fair value of contingent consideration classified as equity are not recognised. The results of subsidiaries acquired or disposed of during the year are included in the consolidated Income Statement from the effective date of acquisition or up to the effective date of disposal, as appropriate. All significant inter-company transactions and balances are eliminated on consolidation. In the Company’s financial statements, investments in subsidiaries are recognised at their cost, less any adjustment for impairment. An associate is an entity over which the Group has significant influence and that is neither a subsidiary nor an interest in a joint venture. Significant influence is the power to participate in the financial and operating policy decisions of the investee but is not control or joint control over those policies. Investments in associates are incorporated in the Group financial statements using the equity method of accounting. Under the equity method, investments in associates are carried in the statement of financial position at cost as adjusted for post-acquisition changes in the Group’s share of the net assets of the associate, less any impairment in the value of individual investments. Losses of an associate in excess of the Group’s interest in that associate (which includes any long-term interests that, in substance, form part of the Group’s net investment in the associate) are recognised only to the extent that the Group has incurred legal or constructive obligations or made payments on behalf of the associate. Where necessary, adjustments are made to bring the associates accounting policies into line with those of the Group. Any excess of the cost of acquisition over the Group’s share of the net fair value of the identifiable assets, liabilities and contingent liabilities of the associate recognised at the date of acquisition is recognised as goodwill. The goodwill is included within the carrying amount of the investment and is assessed for impairment as part of that investment. The Group’s goodwill accounting policy is set out below. Any excess of the Group’s share of the net fair value of the identifiable assets, liabilities and contingent liabilities over the cost of acquisition, after reassessment, is recognised immediately in profit or loss. Where a group entity transacts with an associate of the Group, profits and losses are eliminated to the extent of the Group’s interest in the relevant associate. b) Goodwill Goodwill arising on the acquisition of the subsidiary is recognised as an asset at the date that control is acquired (the acquisition date). Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any non-controlling interest in the acquiree and the fair value of the acquirer’s previously-held equity interest (if any) in the acquiree over the fair value of the identifiable net assets recognised. If, after reassessment, the Group’s interest in the fair value of the acquiree’s identifiable net assets exceeds the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree and the fair value of the acquirer’s previously-held equity interests (if any) in the acquiree, the excess is recognised immediately in profit or loss as a bargain purchase gain. Goodwill is not amortised, but is reviewed for impairment at least annually. For the purpose of impairment testing, goodwill is allocated to each of the Group’s cash-generating units expected to benefit from the synergies of the combination. Cash-generating units to which goodwill has been allocated are tested for impairment annually, or more frequently when there is an indication that the unit may be impaired. The recoverable amount is the higher of fair value less cost to sell and value in use. If the recoverable amount of the cash generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit. Any impairment loss is recognised immediately in profit or loss and is not subsequently reversed. c) Indefinite Life Intangible Assets Indefinite life intangible assets represent purchased brand names and trademarks and are initially recognised at cost. Such intangible assets are regarded as having indefinite useful lives and they are tested annually for impairment on the same basis as for goodwill. d) Finite Life Intangible Assets Finite life intangible assets are recorded at cost less accumulated amortisation. Amortisation is charged on a straight line basis over their estimated useful life. The estimated useful life of finite life intangible assets is 1 to 10 years. The estimated useful life and amortisation period is reviewed at the end of each annual reporting period. e) Intangible Assets Acquired in a Business Combination All potential intangible assets acquired in a business combination are identified and recognised separately from goodwill where they satisfy the definition of an intangible asset and their fair value can be measured reliably. f) Property, Plant, and Equipment The Group has five classes of property, plant and equipment: • Freehold land; • Buildings; • Leasehold improvements; • Plant and vehicles, and • Office equipment, furniture and fittings. Property, Plant and Equipment is initially recorded at cost. Cost includes the original purchase consideration and those costs directly attributable to bring the item of Property, Plant and Equipment to the location and condition for its intended use. After recognition as an asset Property, Plant and Equipment is carried at cost less accumulated depreciation and impairment losses. NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 When an item of Property, Plant and Equipment is disposed of, any gain or loss is recognised in the Income Statement and is calculated as the difference between the sale price and the carrying value of the item. Depreciation is provided for on a straight line basis on all Property, Plant and Equipment other than freehold land, at depreciation rates calculated to allocate the assets’ cost less estimated residual value, over their estimated useful lives. Leased assets are depreciated over the shorter of the unexpired period of the lease and the estimated useful life of the assets. The following useful lives are used in the calculation of depreciation: • Buildings • Leasehold improvements • Plant and vehicles • Office equipment, furniture and fittings g) Impairment of Assets 20 to 100 years 2 to 15 years 2 to 20 years 2 to 10 years At each balance sheet date, the Group reviews the carrying amounts of its non-current assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where the asset does not generate cash flows that are independent from other assets, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs. Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised as an expense immediately. Where an impairment loss subsequently reverses, other than for Goodwill and indefinite life intangible assets, the carrying amount of the asset (cash-generating unit) is increased to the revised estimate of its recoverable amount, but only to the extent that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (cash-generating unit) in prior years. A reversal of an impairment loss is recognised as income immediately. Impairment losses can not be reversed for Goodwill and indefinite life intangible assets. h) Taxation The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the income statement because it excludes items of income and expense that are taxable or deductible in other years and further excludes items that are never taxable or deductible. The Group’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the balance sheet date. Deferred tax is recognised on differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit, and is accounted for using the balance sheet liability method. Deferred tax liabilities are generally recognised for all taxable temporary differences, and deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. Such assets and liabilities are not recognised if the temporary difference arises from goodwill or from the initial recognition (other than in a business combination) of other assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit. Deferred tax liabilities are recognised for taxable temporary differences associated with investments in subsidiaries and associates, except where the Group is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences associated with such investments and interests are only recognised to the extent that it is probable that there will be sufficient taxable profits against which to utilise the benefits of the temporary differences and they are expected to reverse in the foreseeable future. The carrying amount of deferred tax assets is reviewed at each balance sheet date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the balance sheet date. The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner which the Group expects, at the reporting date, to recover or settle the carrying amount of its assets and liabilities. Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the Group intends to settle its current tax assets and liabilities on a net basis. Current and deferred tax are recognised as an expense or income in profit or loss, except when they relate to items recognised in other comprehensive income or directly in equity, in which case the tax is also recognised in other comprehensive income or directly in equity, or where they arise from the initial accounting for a business combination. In the case of a business combination, the tax effect is taken into account in calculating goodwill or in determining the excess of the acquirer’s interest in the net fair value of the acquiree’s identifiable assets, liabilities and contingent liabilities over the cost of the business combination. i) Inventories Inventories are recognised at the lower of cost, determined on a weighted average basis, and net realisable value. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. Net realisable value represents the estimated selling price in the ordinary course of business, less all estimated costs of completion and costs to be incurred in marketing, selling and distribution. EBOS Annual Report 2014 | 11 1. SUMMARY OF ACCOUNTING POLICIES continued j) Leases The Group leases certain plant and equipment and land and buildings. Finance leases, which effectively transfer to the Group substantially all of the risks and benefits incident to ownership of the leased item, are capitalised at the present value of the minimum lease payments. The leased assets and corresponding liabilities are recognised and the leased assets are depreciated over the period the Group is expected to benefit from their use. Lease payments are apportioned between finance charges and reduction of the lease obligation so as to achieve a constant rate of interest on the remaining balance of the liability. Finance charges are charged directly to the Income Statement. Operating lease payments, where the lessors effectively retain substantially all the risks and benefits of ownership of the lease items, are included in the determination of the net surplus in equal instalments over the period of the lease. Lease incentives received are recognised as an integral part of the total lease payments made and also spread on a basis representative of the pattern of benefits expected to be derived from the leased asset. k) Foreign Currency Translation Functional and Presentation Currency The financial statements of each of the Group’s entities are measured using the currency of the primary economic environment in which the entity operates (“the functional currency”). The consolidated financial statements are presented in New Zealand dollars, which is the Company’s functional currency and the Group’s presentation currency. Transactions and Balances Foreign currency transactions are translated into the functional currency using the exchange rates prevailing on the dates of the transactions. At each balance sheet date, monetary assets and liabilities that are denominated in foreign currencies are retranslated at the rates prevailing on the balance sheet date. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are not retranslated. Exchange differences arising on the settlement of monetary items, and on the retranslation of monetary items, are included in the Income Statement for the period. Foreign Operations On consolidation, the assets and liabilities of the Group’s overseas operations are translated at exchange rates prevailing at the reporting date. Income and expense items are translated at the average rates for the period. Exchange differences arising, if any, are recognised in the foreign currency translation reserve, and recognised in profit or loss on disposal of the foreign operation. Goodwill and fair value adjustments arising on the acquisition of a foreign entity are treated as assets and liabilities of the foreign entity and translated at exchange rates prevailing at the reporting date. l) Goods & Services Tax Revenues, expenses, liabilities and assets are recognised net of the amount of goods and services tax (GST), except for receivables and payables which are recognised inclusive of GST. Cash flows are included in the cash flow statement on a net basis. The GST component of cash flows arising from investing and financing activities which is recoverable from, or payable to, the taxation authority is classified as operating cash flows. m) Financial Instruments Financial assets and financial liabilities are recognised on the Group’s balance sheet when the Group becomes a party to the contractual provisions of the instrument. Financial Assets Financial assets are classified into the following specific categories: “financial assets at fair value through profit or loss” (FVTPL), “held to maturity” investments, “available for sale” (AFS) financial assets and “loans and receivables”. The category depends on the nature and purpose of the financial assets and is determined at initial recognition. The categories used are set out below: Cash & Cash Equivalents: Cash and cash equivalents comprise cash on hand and demand deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of changes in value. Financial Assets at Fair Value through Profit and Loss (FVTPL): Derivative assets are classified as FVTPL unless hedge accounting is applied. Financial assets at FVTPL are stated at fair value, with any resultant gain or loss recognised in profit or loss. The net gain or loss recognised in profit or loss incorporates any dividend or interest earned on the financial asset. Loans and Receivables: Trade and other receivables, including advances to subsidiaries, that have fixed or determinable payments that are not quoted in an active market are classified as loans and receivables. Loans and receivables are measured at initial recognition at fair value, and are subsequently measured at amortised cost using the effective interest method. Appropriate allowances for estimated irrecoverable amounts are recognised in the Income Statement when there is objective evidence that the asset is impaired. The allowance recognised is measured as the difference between the asset’s carrying amount and the present value of estimated future cash flows discounted at the effective interest rate computed at initial recognition. Equity Instruments Equity instruments issued by the Company are recorded at the proceeds received, net of direct issue costs. Financial Liabilities Financial liabilities are classified as either financial liabilities at “fair value through profit or loss” (FVTPL) or “other financial liabilities” measured at amortised cost. The classifications used are set out below: Financial Liabilities at Fair Value through Profit and Loss: Derivative liabilities are classified as FVTPL unless hedge accounting is applied. NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 Financial liabilities at FVTPL are stated at fair value, with any resultant gain or loss recognised in profit or loss. The net gain or loss recognised in profit or loss incorporates any dividend or interest paid on the financial liability. Other Financial Liabilities: Trade and other payables, including advances from subsidiaries and bank loans, are initially measured at fair value, and subsequently measured at amortised cost, using the effective interest method. All loans and borrowings are initially recognised at cost, being the fair value of the consideration received plus issue costs associated with the borrowing. After initial recognition, these loans and borrowings are subsequently measured at amortised cost using the effective interest method which allocates the cost through the expected life of the loan or borrowing. Amortised cost is calculated taking into account any issue costs, and any discount or premium on drawdown. Bank loans are classified as current liabilities (either advances or current portion of term debt) unless the Group has an unconditional right to defer settlement of the liability for at least 12 months after the balance sheet date. Derivative Financial Instruments The Group enters into foreign currency forward exchange contracts to hedge trading transactions, including anticipated transactions, denominated in foreign currencies and from time to time uses interest rate swaps to manage cash flow interest rate risk. Derivatives are initially recognised at fair value on the date a derivative contract is entered into and are subsequently remeasured to their fair value. The resulting gain or loss is recognised in profit or loss immediately unless the derivative is designated and effective as a hedging instrument, in which event the timing of the recognition in profit or loss depends on the nature of the hedge relationship. The Group designates certain derivatives as cashflow hedges of highly probable forecast transactions. Cashflow Hedges At the inception of the hedge relationship, the Group documents the relationship between the hedging instrument and the hedged item, along with its risk management objectives and its strategy for undertaking various hedge transactions. Furthermore, at the inception of the hedge and on an on-going basis, the Group documents whether the hedging instrument that is used in a hedging relationship is highly effective in offsetting changes in cashflows of the hedged items. The effective portion of changes in the fair value of derivatives that are designated and qualify as cashflow hedges are recognised in other comprehensive income and accumulated as a separate component of equity in the hedge reserve. The gain or loss relating to the ineffective portion is recognised immediately in profit or loss. Amounts deferred in equity are recycled in profit or loss in the periods when the hedged item is recognised in profit or loss. However, when the forecast transaction that is hedged results in the recognition of a non-financial asset or a non-financial liability, the gains and losses previously deferred in equity are transferred from equity and included in the initial measurement of the cost of the asset or liability. Hedge accounting is discontinued when the Group revokes the hedging relationship, the hedging instrument expires, is terminated, exercised or no longer qualifies for hedge accounting. Any cumulative gain or loss deferred in equity at that time remains in equity and is recognised when the forecast transaction is ultimately recognised in profit or loss. When a forecast transaction is no longer expected to occur, the cumulative gain or loss that was deferred in equity is recognised immediately in profit or loss. n) Revenue Recognition Revenue is measured at the fair value of the consideration received or receivable and represents amounts receivable for goods and services provided in the normal course of business, net of returns, discounts, allowances and GST. Revenue is recognised when it is considered probable that the economic benefits of the transaction will be received. The following specific recognition criteria must be met before revenue is recognised: Sale of Goods Sales of goods are recognised when significant risks and rewards of owning the goods are transferred to the buyer, when the revenue can be measured reliably and when management effectively ceases involvement or control. Rendering of Services Revenue from services rendered is recognised when it is probable that the economic benefits associated with the transaction will flow to the entity. The stage of completion at balance date is assessed based on the value of services performed to date as a percentage of the total services to be performed. Interest Income Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset’s net carrying amount. Effective Interest Method The effective interest method is a method of calculating the amortised cost of a financial asset and of allocating interest income over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts (including all fees on points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the financial asset, or, where appropriate, a shorter period to the carrying amount of the financial asset. Royalties Royalty revenue is recognised on an accrual basis in accordance with the substance of the relevant agreement. Royalties determined on a time basis are recognised on a straight line basis over the period of the agreement. Royalty arrangements that are based on production, sales and other measures are recognised by reference to the underlying agreement. Dividend Income Dividend income from investments is recognised when the shareholders’ rights to receive payment have been established. EBOS Annual Report 2014 | 13 1. SUMMARY OF ACCOUNTING POLICIES continued o) Cash Flow Statement q) Segment Reporting The cash flow statement is prepared exclusive of GST, which is consistent with the method used in the income statement. Definition of terms used in the cash flow statement: Operating activities include all transactions and other events that are not investing or financing activities. Investing activities are those activities relating to the acquisition and disposal of current and non-current investments and any other non-current assets. Financing activities are those activities relating to changes in the equity and debt capital structure of the Company and Group and those activities relating to the cost of servicing the Company’s and the Group’s equity capital. p) Employee Entitlements A liability for annual leave and long service leave is accrued and recognised in the statement of financial position. The liability is equal to the present value of the estimated future cash outflows as a result of employee services provided at balance date. Provisions are classified as non-current only if the Group has a legal entitlement not to make payment within a 12 month period, to the employee in which the obligation has been accrued. Provisions made in respect of employee benefits expected to be settled within 12 months are measured at their nominal values using the remuneration rate expected to apply at the time of settlement. Provisions made in respect of employee benefits which are not expected to be settled within 12 months are measured at the present value of the estimated future cash outflows to be made by the Group in respect of services provided up to reporting date. The Group’s operating segments are identified on the basis of internal reports about components of the Group that are regularly reviewed by the chief operating decision maker (Chief Executive Officer) in order to allocate resources to the segment and to assess its performance. r) Adoption of New Revised Standards and interpretations The Group has applied NZ IFRS 13 ‘Fair Value Measurement’ for the first time in the current year. NZ IFRS 13 establishes a single source of guidance for fair value measurements and disclosures about fair value measurements. NZ IFRS 13 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction in the principal (or most advantageous) market at the measurement date under current market conditions. Fair value under NZ IFRS 13 is an exit price regardless of whether that price is directly observable or estimated using another valuation technique. Other than additional disclosures, the application of NZ IFRS 13 has not had any material impact on the amounts recognised in these financial statements. No other standards have been adopted during the year which has had a material impact on these financial statements. The Group has not yet fully assessed the impact of NZ IFRS 15 ‘Revenue from Contracts with Customers’ which will be effective from the 2018 financial year. NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 2. PROFIT FROM OPERATIONS (a) Revenue Revenue consisted of the following items: Revenue from the sale of goods - external Revenue from the sale of goods - inter group Revenue from the rendering of services Management fees - inter group Interest revenue - inter group Interest revenue - external Royalty income - inter group Dividends - inter group (b) Profit before tax expense Profit before tax expense has been arrived at after crediting/(charging) the following gains and losses from operations: Gain/(loss) on disposal of property, plant and equipment Change in fair value of derivative financial instruments Income from associates Profit before tax expense has been arrived at after (charging) the following expenses by nature: Cost of sales - external Purchases inter group Write-down of inventory Finance costs: Bank interest Other interest expense Total finance costs Net bad and doubtful debts arising from: Impairment loss on trade & other receivables Depreciation of property, plant and equipment Amortisation of finite life intangibles Operating lease rental expenses: Minimum lease payments Donations Employee benefit expense Defined contribution plan expenses Costs associated with acquisition of subsidiaries Other expenses Total expenses Profit before tax expense Group 2014 $’000 2013 $’000 Parent 2014 $’000 Notes 2013 $’000 5,671,996 - 85,238 - - 2,819 - - 1,811,465 - 10,506 - - 1,198 - - 57,657 11,484 - 440 1,159 62 2,769 45,775 55,788 10,986 - 440 1,155 233 3,208 39,623 5,760,053 1,823,169 119,346 111,433 (4) (213) 1,567 170 257 585 (21) (213) - (2) 257 - 16 (5,187,151) - (3,771) (1,597,475) - (2,227) (29,335) (542) (29,877) (8,979) (614) (9,593) 10 14 (1,684) (10,173) (12,410) (25,563) (107) (195,232) (11,141) - (158,513) (14) (4,922) (1,514) (9,227) (29) (76,213) (2,927) (5,993) (71,833) (44,850) (2,073) (199) (5,613) - (5,613) (59) (539) - (1,080) (60) (12,487) (398) - (8,883) (43,655) (1,406) (192) (5,019) (9) (5,028) (20) (552) - (1,061) (5) (10,967) (107) (5,993) (7,724) (5,635,622) (1,781,967) (76,241) (76,710) 125,781 42,214 42,871 34,978 EBOS Annual Report 2014 | 15 3. INCOME TAXES (a) Tax expense recognised in income statement Tax expense/(credit) comprises: Current tax expense/(credit): Current year Adjustments for prior years Deferred tax expense/(credit): Origination and reversal of temporary differences Adjustments for prior years Group 2014 $’000 2013 $’000 Parent 2014 $’000 2013 $’000 39,378 700 40,078 (6,133) (233) (6,366) 13,135 860 13,995 171 (159) 12 (318) 292 (26) 304 (14) 290 264 (460) 299 (161) 270 9 279 118 Total tax expense 33,712 14,007 The prima facie tax expense on pre-tax accounting profit from operations reconciles to the tax expense in the financial statements as follows: Profit before tax expense Tax expense calculated at 28% (2013: 28%) (Non-assessable income)/non-deductible expenses Effect of different tax rates of subsidiaries operating in other jurisdictions Under/(over) provision of tax expense in previous year Other adjustments Total tax expense 125,781 42,214 42,871 34,978 35,219 (4,031) 11,820 998 12,004 (12,018) 9,794 (9,984) 1,944 467 113 441 701 47 33,712 14,007 - 278 - 264 - 308 - 118 The tax rates used are principally the corporate tax rates of 28% (2013: 28%) payable by New Zealand and 30% (2013: 30%) payable by Australian corporate entities on taxable profits under tax law in each jurisdiction. (b) Current tax assets and liabilities Current tax assets: Current tax refundable Current tax liabilities: Current tax payable (c) Deferred tax balance Deferred tax assets comprise: Temporary differences Deferred tax liabilities comprise: Temporary differences Group 2014 $’000 2013 $’000 Parent 2014 $’000 83 1,628 14,219 6,378 - - 2013 $’000 722 - 36,589 34,361 252 310 (43,407) (48,365) (6,818) (14,004) (2,279) (2,027) (2,220) (1,910) NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 3. INCOME TAXES continued Taxable and deductible temporary differences arise from the following: 2014 Gross deferred tax liabilities: Property, plant & equipment Provisions Other financial assets - derivatives Intangible assets Gross deferred tax assets: Property, plant and equipment Provisions Other financial liabilities – derivatives Tax losses carried forward Net movement in deferred tax 2013 Gross deferred tax liabilities: Property, plant & equipment Provisions Other financial assets - derivatives Intangible assets Gross deferred tax assets: Property, plant and equipment Provisions Other financial liabilities – derivatives Tax losses carried forward Net movement in deferred tax Group Group Opening balance $’000 Charged to income $’000 Group Charged to other comprehensive income $’000 Acquisitions $’000 Foreign currency movements $’000 Group Group Group (1,773) (9) (290) (46,293) (48,365) 6,211 25,180 1,379 1,591 34,361 (1,936) (26) - (8,918) (10,880) - 4,610 837 1,979 7,426 (209) (12) (248) 1,897 1,428 5,623 (334) - (351) 4,938 6,366 163 17 26 164 370 (30) 148 (215) (285) (382) (12) - - - - - - - - - - - - - (37,926) (37,926) 6,309 20,768 762 - 27,839 - - 170 - 170 - - 531 - 531 701 - - (316) - (316) - - (43) - (43) (359) - (16) 101 3,275 3,360 (592) (2,100) (359) (190) (3,241) - - - 387 387 (68) (346) 38 (103) (479) Closing balance $’000 (1,982) (37) (267) (41,121) (43,407) 11,242 22,746 1,551 1,050 36,589 (1,773) (9) (290) (46,293) (48,365) 6,211 25,180 1,379 1,591 34,361 EBOS Annual Report 2014 | 17 3. INCOME TAXES continued 2014 Gross deferred tax liabilities: Property, plant & equipment Intangible assets Other financial assets – derivatives Gross deferred tax assets: Provisions Doubtful debts & impairment losses Net movement in deferred tax 2013 Gross deferred tax liabilities: Property, plant & equipment Intangible assets Other financial assets - derivatives Gross deferred tax assets: Provisions Doubtful debts & impairment losses Other financial liabilities – derivatives Net movement in deferred tax (d) Imputation credit account balances Imputation credits available directly and indirectly to shareholders of the parent company: Parent Parent Opening balance $’000 Charged to income $’000 Parent Charged to other comprehensive income $’000 (616) (1,389) (215) (2,220) 271 39 310 (637) (1,389) - (2,026) 571 39 35 645 16 - (248) (232) (59) 1 (58) - - 173 173 - - - (290) 173 21 - - 21 (300) - - (300) (279) - - (215) (215) - - (35) (35) (250) Parent Closing balance $’000 (600) (1,389) (290) (2,279) 212 40 252 (616) (1,389) (215) (2,220) 271 39 - 310 Group 2014 $’000 Group 2013 $’000 (660) 1,399 NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 4. KEY MANAGEMENT PERSONNEL COMPENSATION Short-term employee benefits 5. REMUNERATION OF AUDITORS Auditor of the parent entity (Deloitte) Audit of the financial statements Audit related services for review of interim financial statements not included above Investigating accountants report* Due diligence Information technology services Financial modelling assistance Assurance services for indirect tax compliance * These costs have been netted off against share capital. Other auditors of entities in the group Audit of financial statements Other non-audit services Group 2014 $’000 12,137 12,137 2013 $’000 9,625 9,625 Parent 2014 $’000 6,329 6,329 562 177 - - 47 49 17 852 - - - 432 6 105 278 10 92 12 935 224 9 233 51 15 - - 47 - - 113 - - - 2013 $’000 6,942 6,942 64 - 105 258 10 - - 437 - - - All non-audit services provided by the Group’s auditors require pre-approval by the Audit and Risk Committee. Before any non-audit services are approved, the Audit and Risk Committee must be satisfied that the provision of such services will not have any undue influence on the independence of the Groups auditors. 6. TRADE & OTHER RECEIVABLES Trade receivables (i) Other receivables Allowance for impairment (ii) 703,821 11,971 (16,516) 742,028 11,449 (17,048) 699,276 736,429 8,253 107 (143) 8,217 9,678 859 (138) 10,399 (i) Trade receivables are non-interest bearing and generally on monthly terms. Interest may be charged on outstanding overdue balances in accordance with the terms and conditions under which goods are supplied. (ii) Allowance for Impairment Balance at the beginning of the year Arising from businesses acquired Impairment loss recognised on trade receivables Amounts written off as uncollectible Amounts recovered during year Impairment losses reversed Effect of foreign currency exchange differences (17,048) - (1,684) 792 (73) - 1,497 (2,159) (15,329) (222) 280 (7) 208 181 (16,516) (17,048) (138) - (59) 54 - - - (143) (138) - (20) 20 - - - (138) In determining the recoverability of trade and other receivables, the Group considers any change in the credit quality of the trade receivable from the date credit was initially granted up to reporting date. The concentration of credit risk is limited due to the customer base being large and unrelated. Accordingly, the directors believe that there is no further credit provision required in excess of the allowance for doubtful debts. The impairment recognised represents the difference between the carrying amount of these trade receivables and the present value of the expected liquidation proceeds. The Group does not hold any collateral over these balances. The net carrying amount is considered to approximate their fair value. EBOS Annual Report 2014 | 19 6. TRADE & OTHER RECEIVABLES continued (iii) Ageing of impaired trade and other receivables Current 30 - 60 days 60 - 90 days 90 days+ Group 2014 $’000 4,217 3,040 1,303 8,656 17,216 2013 $’000 4,334 2,387 961 12,888 20,570 Parent 2014 $’000 - - - 143 143 2013 $’000 - - - 138 138 (iv) Ageing of past due but not impaired trade and other receivables Included in the trade and other receivables balance are debtors with a carrying amount of Group $62.918m (2013: $82.36m) and Parent $1.527m (2013: $2.217m) which are past due at the reporting date for which the Group and/or Parent has not provided any impairment as the amounts are still considered recoverable. 30 - 60 days 60 - 90 days 90 days+ 7. PREPAYMENTS Current portion Term portion 8. INVENTORIES Finished Goods At cost 9. OTHER FINANCIAL ASSETS - DERIVATIVES At Fair Value: Foreign currency forward contracts (i) Foreign currency forward contracts (ii) Interest rate swaps (ii) 45,952 6,380 10,586 62,918 6,748 54 6,802 65,760 8,785 7,815 82,360 7,837 16 7,853 576 74 877 1,527 941 - 941 1,806 198 213 2,217 838 - 838 491,624 558,350 491,624 558,350 8,912 8,912 9,146 9,146 6 97 1,339 1,442 160 2,615 771 3,546 6 - 1,331 1,337 160 885 771 1,816 (i) Financial asset carried at fair value through profit or loss (“FVTPL”). (ii) Designated and effective as cash flow hedging instrument carried at fair value. The Group has categorised these derivatives, both financial assets (as above) and financial liabilities (refer to Note 20), as Level 2 under the fair value hierarchy contained within NZ IFRS 13. The fair value of forward foreign exchange contracts is determined using a discounted cashflow valuation. Key inputs include observable forward exchange rates, at the measurement date, with the resulting value discounted back to present values. Interest rate swaps are valued using a discounted cashflow valuation. Key inputs for the valuation of interest rate swaps are the estimated future cash flows based on observable yield curves at the end of the reporting period, discounted at a rate that reflects the credit risk of the various counterparties. There have been no changes in valuation techniques used for either forward foreign exchange contracts or interest rate swaps during the current reporting period. There were no transfers between fair value hierarchy levels during the current or prior periods. NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 10. PROPERTY, PLANT AND EQUIPMENT Gross carrying amount Balance at 1 July, 2012 Additions Disposals Acquisition through business combinations Net foreign currency exchange differences Balance at 30 June, 2013 Additions Disposals Net foreign currency exchange differences Group Freehold land at cost $’000 Buildings at cost $’000 Leasehold improvement at cost $’000 Plant and vehicles at cost $’000 2,076 - (49) 28,529 (316) 30,240 - - (2,595) 9,273 4 (90) 10,238 (131) 19,294 56 - (950) 3,001 120 (128) 7,252 (182) 10,063 555 (13) (783) 12,963 1,569 (667) 21,675 (630) 34,910 5,171 (2,863) (2,489) Office equipment furniture & fittings at cost $’000 14,455 792 (1,083) 7,810 (266) Total $’000 41,768 2,485 (2,017) 75,504 (1,525) 21,708 116,215 2,611 (5,399) (936) 8,393 (8,275) (7,753) Balance at 30 June, 2014 27,645 18,400 9,822 34,729 17,984 108,580 Accumulated depreciation Balance at 1 July, 2012 Disposals Depreciation expense Net foreign currency exchange differences Balance at 30 June, 2013 Disposals Depreciation expense Net foreign currency exchange differences Balance at 30 June, 2014 Net book value As at 30 June, 2013 As at 30 June, 2014 - - - - - - - - - (2,321) 42 (367) 9 (2,637) - (944) 25 (3,556) (1,256) 95 (476) 64 (1,573) 13 (1,124) 95 (2,589) (5,401) 562 (2,016) 174 (6,681) 2,458 (4,833) 397 (8,659) (9,301) 1,067 (2,063) 104 (18,279) 1,766 (4,922) 351 (10,193) (21,084) 4,357 (3,272) 186 (8,922) 6,828 (10,173) 703 (23,726) 30,240 27,645 16,657 14,844 8,490 7,233 28,229 26,070 11,515 9,062 95,131 84,854 EBOS Annual Report 2014 | 21 10. PROPERTY, PLANT & EQUIPMENT continued Parent Freehold land at cost $’000 Buildings at cost $’000 Leasehold improvement at cost $’000 Plant and vehicles at cost $’000 694 - - 694 - - 2,920 - - 2,920 - - 117 14 - 131 6 - 1,394 113 (300) 1,207 103 (52) Office equipment furniture & fittings at cost $’000 1,369 107 (267) 1,209 548 (9) Total $’000 6,494 234 (567) 6,161 657 (61) Gross carrying amount Balance at 1 July, 2012 Additions Disposals Balance at 30 June, 2013 Additions Disposals Balance at 30 June, 2014 694 2,920 137 1,258 1,748 6,757 Accumulated depreciation Balance at 1 July, 2012 Disposals Depreciation expense Balance at 30 June, 2013 Disposals Depreciation expense Balance at 30 June, 2014 Net book value As at 30 June, 2013 As at 30 June, 2014 - - - - - - - (381) - (80) (461) - (77) (538) 694 694 2,459 2,382 Aggregate depreciation recognised as an expense during the year: Buildings Leasehold improvements Plant and vehicles Office equipment, furniture & fittings 11. CAPITAL WORK IN PROGRESS Capital work in progress - - (13) (13) - (13) (26) 118 111 Group 2014 $’000 944 1,124 4,833 3,272 10,173 Group 2014 $’000 20,872 (492) 287 (205) (410) 35 (202) (577) 797 681 2013 $’000 367 476 2,016 2,063 4,922 2013 $’000 787 (622) 267 (254) (609) 4 (247) (852) 600 896 Parent 2014 $’000 77 13 202 247 539 Parent 2014 $’000 - (1,495) 554 (552) (1,493) 39 (539) (1,993) 4,668 4,764 2013 $’000 80 13 205 254 552 2013 $’000 - The capital work in progress relates to a custom built warehouse ($20,058,000) – the cost to complete the project is $4,384,000, and software development ($814,000) – the cost to complete the project is $138,000. The 2013 capital work in progress related to software development ($469,000) – there were no further costs to complete the project, and a refrigeration system ($318,000) – the cost to complete the project was $138,000. NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 12. GOODWILL Gross carrying amount Balance at beginning of financial year Recognised on acquisition during the year Effects of foreign currency exchange differences Net book value Allocation of goodwill to cash-generating units Group 2014 $’000 2013 $’000 722,158 - (1,283) 180,553 542,736 (1,131) 720,875 722,158 Parent 2014 $’000 1,728 - - 1,728 Goodwill has been allocated for impairment testing purposes to the following cash generating units representing the lowest level at which management monitor goodwill: • Australian Hospital, Pharmacy and Primary Healthcare sector: Healthcare Australia. • New Zealand Consumer, Hospital, Primary Healthcare, Aged Care and International Product Supplies: Healthcare NZ. • New Zealand Pharmacy Wholesaler and Logistic Services: Healthcare - Pharmacy/Logistics NZ. • New Zealand Animal care sector: Animal care – NZ. • Australian Animal care sector: Animal care – Australia. The carrying amount of goodwill allocated to cash-generating units is as follows: Healthcare Australia Healthcare NZ (Parent) Healthcare – Pharmacy/Logistics NZ Animal care – NZ Animal care – Australia Group 2014 $’000 502,627 1,728 95,043 66,375 55,102 2013 $’000 503,910 1,728 95,043 66,375 55,102 720,875 722,158 Parent 2014 $’000 - 1,728 - - - 1,728 2013 $’000 1,728 - - 1,728 2013 $’000 - 1,728 - - - 1,728 During the year ended 30 June 2014, management have determined that there is no impairment of any of the cash generating units containing goodwill (2013: Nil). The recoverable amounts (i.e. higher of value in use and fair value less costs to sell) of those units are determined on the basis of value in use calculations. Management has determined that the recoverable amount calculations are most sensitive to changes in the following assumptions: Market shares during the assessment period are assessed by management based on average market shares achieved in the period immediately before the start of the budget period, adjusted each year for any anticipated growth. Gross margins during the assessment period are estimated by management based on average gross margins achieved before the start of the assessment period, adjusted for expected changes in the business or sector in which the business operates. Operating costs during the assessment period are estimated by management based on current trends at the start of the assessment period, adjusted for expected changes in the business or sector in which the business operates. The value in use calculation uses cash flow projections based on financial forecasts approved by management covering a five year period and managements past experience. Annual growth rates of 0.9% to 4.6% (2013: 1.4% to 5%), an allowance of 1.0% to 4.5% (2013: 1.4% to 5%) for increase in expenses, and pre tax discount rates of 12.7% to 17.4% (2013: 13.1% to 17.4%) have been applied to these projections. Cash flows beyond the five year period have been extrapolated using a 2% to 2.5% (2013: 2% to 2.5%) growth rate. Management also believes that any reasonable possible change in the key assumptions would not cause the carrying amount of any of the cash generating units to exceed their recoverable amount. EBOS Annual Report 2014 | 23 Group Other Pharmacy Brands $’000 Group Masterpet Brand & Intangibles $’000 Group Group Trademarks $’000 Total $’000 Group Symbion Brands $’000 - 28,871 (310) 28,561 (2,615) 25,946 28,561 25,946 13. INDEFINITE LIFE INTANGIBLES Gross carrying amount Balance at 1 July, 2012 Recognised on acquisition during the year Net foreign currency exchange differences Balance at 30 June, 2013 Net foreign currency exchange differences Balance at 30 June, 2014 Net book value As at 30 June, 2013 As at 30 June, 2014 Gross carrying amount Balance at 1 July, 2012 Balance at 30 June, 2013 Balance at 30 June, 2014 Net book value As at 30 June, 2013 As at 30 June, 2014 7,110 - - 7,110 - 7,110 7,110 7,110 17,240 - - 17,240 - 17,240 17,240 17,240 6,531 - (118) 6,413 (133) 6,280 6,413 6,280 Parent Other Pharmacy Brands $’000 4,960 4,960 4,960 4,960 4,960 The carrying amount of indefinite life intangibles (brands and trademarks) has been allocated to the cash generating units as follows: Healthcare Australia Healthcare NZ Healthcare - Pharmacy/Logistics NZ Animal care NZ Group 2014 $’000 29,836 2,390 17,240 7,110 56,576 Management have assessed these as having an indefinite useful life. In coming to this conclusion management considered expected expansion of the usage of the brands across other products and markets, the typical product life cycle of these assets, the stability of the industry in which the brands are operating, the level of maintenance expenditure required and the period of legal control over the brands. During the current year management have determined that there is no impairment of any of the brands (2013: Nil). The calculation of the recoverable amounts for indefinite life intangibles have been determined based on a value in use calculation that uses cash flow projections based on financial forecasts approved by management covering a five-year period. Management has determined that the recoverable amount calculations are most sensitive to change in the following assumptions. Annual growth rates of 1.4% to 3% (2013: 1.4% to 3%), and an allowance of 1.4% to 3% (2013: 1.4% to 3%) for increases to expenses, and pre-tax discount rates of 13.1% to 19.2% (2013: 12.9% to 19.2%) have been applied to these projections. Cash flows beyond the five-year period have been extrapolated using a 2% to 2.5% (2013: 2% to 2.5%) growth rate. Management also believes that any reasonably possible change in the key assumptions would not cause the carrying amount of the brands to exceed their recoverable amount. 30,881 28,871 (428) 59,324 (2,748) 56,576 59,324 56,576 Parent Total $’000 4,960 4,960 4,960 4,960 4,960 2013 $’000 32,584 2,390 17,240 7,110 59,324 NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 14. FINITE LIFE INTANGIBLES Gross carrying amount Balance at 1 July 2012 Recognised on acquisition during the year Other additions Net foreign exchange differences Balance at 30 June 2013 Balance at 30 June 2013 Other additions Net foreign exchange differences Balance at 30 June 2014 Accumulated amortisation & impairment Balance at 1 July 2012 Amortisation expense Net foreign exchange differences Balance at 30 June 2013 Balance at 30 June 2013 Amortisation expense Net foreign exchange differences Balance at 30 June 2014 Net book value As at 30 June 2013 As at 30 June 2014 Allocated to cash generating units as follows: Animal care - NZ Animal care - Australia Healthcare Australia Pharmacy/Logistics NZ Group Group Supply Contracts $’000 Software $’000 Group Customer Relationships/ Contracts $’000 Total $’000 1,490 - - - 1,490 1,490 - - 1,490 (1,458) (32) - (1,490) (1,490) - - (1,490) 330 1,853 142 (67) 2,258 2,258 3,148 (228) 5,178 (83) (367) 35 (415) (415) (1,818) 93 (2,140) - 95,443 - (1,026) 94,417 94,417 - (8,646) 85,771 - (1,115) - (1,115) (1,115) (10,592) 400 (11,307) 1,820 97,296 142 (1,093) 98,165 98,165 3,148 (8,874) 92,439 (1,541) (1,514) 35 (3,020) (3,020) (12,410) 493 (14,937) - - 1,843 3,038 93,302 74,464 95,145 77,502 2014 $’000 251 11,191 65,373 687 77,502 2013 $’000 127 13,976 81,042 - 95,145 EBOS Annual Report 2014 | 25 15. SUBSIDIARIES Parent and Head Entity EBOS Group Limited The following entities comprise the trading and holding companies of the Group: Subsidiaries (all balance dates 30 June) EBOS Healthcare (Australia) Pty Limited EBOS Group Australia Pty Limited EBOS Health & Science Pty Limited PRNZ Limited Pharmacy Retailing NZ Limited EBOS Limited Partnership Healthcare Distributors Pty Limited Masterpet Corporation Limited Natures Recipe Pet Foods Limited Masterpet Australia Pty Limited Botany Bay Imports and Exports Pty Limited Aristopet Pty Ltd (formerly Beaphar Australia Pty Limited) EBOS Australia Holdings Pty Limited ZHHA Pty Ltd ZAP Services Pty Ltd Symbion Pty Ltd Intellipharm Pty Ltd Clinect Pty Ltd Lyppard Australia Pty Ltd APHS Packaging Pty Ltd Symbion Pharmacy Services Trade Receivables Trust Country of Incorporation Australia Australia Australia New Zealand New Zealand Australia Australia New Zealand New Zealand Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Australia Ownership Interests and Voting Rights 2014 2013 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 16. INVESTMENT IN ASSOCIATES Name of business acquired Principal activities Date of acquisition Proportion of shares and voting rights acquired Cost of acquisition $’000 Animates NZ Holdings Limited VIM Health Pty Limited Animal care supplies Healthcare supplies December 2011 December 2013 50% 50% 18,150 3,520 The reporting date for Animates NZ Holdings Limited is 30 June. Animates NZ Holdings Limited is incorporated in New Zealand. The reporting date for VIM Health Pty Limited is 30 June. VIM Health Pty Limited is incorporated in Australia. Although the company holds 50% of the shares and voting power in both Animates NZ Holdings Limited and VIM Health Pty Limited these entities are not deemed to be a subsidiary as the other 50% is held by other single shareholders in both cases, therefore the Group is unable to exercise control over these entities. The summary financial information in respect of the Group’s associates is set out below: Statement of financial position Total assets Total liabilities Net assets Group’s share of net assets Income Statement Total revenue Total profit for the period Group’s share of profits of associates Movement in the carrying amount of the group’s investment in associates: Balance at beginning of financial year New investments Share of equity accounted investments Balance at end of financial year 2014 $’000 2013 $’000 41,620 (24,480) 17,140 8,570 68,522 3,134 1,567 28,461 (21,512) 6,949 3,475 56,061 1,170 585 2014 $’000 2013 $’000 19,013 3,520 1,567 24,100 18,428 - 585 19,013 Goodwill included in the carrying amount of the Group’s investment in associates 15,945 15,945 The Group’s share of the contingent liabilities of associates The Group’s share of capital commitments of associates - - - - EBOS Annual Report 2014 | 27 17. BORROWINGS Current Bank loans (i) Bank loans – securitisation facility (ii) Finance lease liabilities (iii) Advances from Subsidiaries (at call) (iv) Non-current Bank loans (i) Finance lease liabilities (iii) Total borrowings Group 2014 $’000 2013 $’000 22,755 130,579 155 - 21,798 193,877 1,189 - Parent 2014 $’000 4,000 - - 29,319 2013 $’000 4,000 - - 29,319 153,489 216,864 33,319 33,319 250,826 680 151,357 3,296 251,506 154,653 85,500 - 85,500 87,412 - 87,412 404,995 371,517 118,819 120,731 (i) The Group has bank term loans and revolving cash advance facilities of $361.2m (2013: $196.3m), of which $87.6m was unutilised at 30 June 2014 (2013: $69.5m), which operate under a negative pledge deed provided to ANZ National Bank Limited, Bank of New Zealand Limited and National Australia Bank Limited by the parent company and its subsidiaries. There have been no breaches of the banking covenants. (ii) The Group, through a subsidiary company, has a trade debtor securitisation facility of $450.3m (2013: $496.7m) of which $319.7m was unutilised at 30 June 2014 (2013: $302.8m). The securitisation facility involves Symbion Pty Limited providing security over the future cash flows of specific trade receivables of Symbion Pty Limited, which meet certain criteria, in return for cash finance on a contracted percentage of the security provided. As recourse, in the event of default by a trade debtor, remains with Symbion Pty Limited the trade receivables provided as security and the funding provided are recognised on the Group’s balance sheet. Interest is charged on the average daily balance of the funding provided under the securitisation facility. At 30 June 2014, the value of trade receivables as security under this securitisation facility was $180.3m (2013: $283.8m). The net cash flows associated with the securitisation programme are disclosed in the cash flow statement as cash flows from financing activities. The Symbion Pharmacy Services Trade Receivables Trust (“SPS Trust”), which is consolidated, was established solely for the purpose of purchasing qualifying trade receivables from Symbion Pty Limited and funding the same from lenders. The SPS Trust has directly provided funding to Symbion Pty Limited to acquire the rights to the cashflows of the securitised receivables. SPS Trust is consolidated as the Group has the exposure, or rights, to variable returns from its involvement with the Trust and the Group considers that it has existing rights that give it the current ability to direct the relevant activities of the Trust. (iii) Secured by the assets leased. (iv) Unsecured. The fair value of non current borrowings is approximately equal to their carrying amount. Subsequent to year end, in August 2014, the Group renegotiated some of the terms and conditions of its securitisation and term debt facilities: • This renegotiation included an extension of the expiry date of the securitisation facility to August 2017, previously September 2015, and a voluntary reduction in the available facility limit from NZ$450.3m (A$420m) to NZ$412.8m (A$385m). • The term of the Group’s existing bank debt facilities have also been extended as part of these renegotiations. As a result the maturity profile of the Group’s term debt, working capital and securitisation facilities are now: Facility Amount (NZD) Term debt facilities Term debt facilities Term debt facilities Working capital facilities Securitisation facility $82.5m $93.3m $94.0m $90.5m $412.8m Maturity August 2016 August 2018 August 2019 July 2015 August 2017 NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 18. TRADE & OTHER PAYABLES Current Trade payables Other payables Non-current Other payables Total trade & other payables 19. LEASES Finance leases Minimum future lease payments Group 2014 $’000 2013 $’000 775,774 45,617 824,704 67,941 821,391 892,645 Parent 2014 $’000 3,809 2,547 6,356 2013 $’000 4,344 4,828 9,172 9,778 8,489 - - 831,169 901,134 6,356 9,172 Finance leases relate to office equipment, plant and motor vehicles. The Group has options to purchase the equipment for a nominal amount at the conclusion of the lease agreements. Finance lease liabilities Not later than 1 year Later than 1 year and not later than 5 years Minimum lease payments* Less future finance charges Present value of minimum lease payments Included in the financial statements as: Finance leases - current portion Finance leases - non current portion Minimum Future Lease Payments Group 2014 $’000 167 701 868 (33) 835 Parent 2014 $’000 - - - - - 2013 $’000 1,504 3,590 5,094 (609) 4,485 Present Value of Minimum Future Lease Payments Group Parent 2013 $’000 2014 $’000 2013 $’000 2014 $’000 2013 $’000 - - - - - 155 680 835 - 835 155 680 835 1,189 3,296 4,485 - 4,485 1,189 3,296 4,485 - - - - - - - - - - - - - - - - * Minimum future lease payments includes the aggregate of all lease payments and any guaranteed residual. The fair value of the finance lease liabilities is approximately equal to their carrying value. Operating leases Leasing arrangements Operating leases relate to certain property and equipment, with lease terms of between one to fifteen years with options to extend for a further one to fifteen years. All operating lease contracts contain market review clauses in the event that the Company/Group exercises its option to renew. The Company/Group does not have an option to purchase the leased asset at the expiry of the lease period. Operating leases Non-cancellable operating lease payments Not longer than 1 year Longer than 1 year and not longer than 5 years Longer than 5 years Group 2014 $’000 2013 $’000 Parent 2014 $’000 22,422 67,408 54,631 23,701 72,114 48,209 144,461 144,024 966 3,101 1,848 5,915 2013 $’000 1,021 2,943 2,520 6,484 EBOS Annual Report 2014 | 29 20. OTHER FINANCIAL LIABILITIES - DERIVATIVES At fair value: Foreign currency forward contracts (i) Foreign currency forward contracts (ii) Interest rate swaps (ii) (i) Financial liability carried at fair value through profit or loss (“FVTPL”). (ii) Designated and effective as cashflow hedging instrument carried at fair value. 21. SHARE CAPITAL Group 2014 $’000 59 894 2,451 3,404 2013 $’000 - - 2,872 2,872 Parent 2014 $’000 2013 $’000 59 - 293 352 - - - - 2014 No. ’000 2014 $’000 2013 No. ’000 2013 $’000 Fully paid ordinary shares Balance at beginning of financial year Issue of shares to executives and staff under employee share ownership scheme 65,546 - 201,288 - 52,107 63 107,970 250 Dividend reinvested – October 2012 – April 2013 – October 2013 – April 2014 Bonus issue – June 2013 Institutional placement – June 2013 Share issue costs Rights issue – July 2013 Share issue costs Issue of consideration shares – July 2013 Share issue costs - - 996 1,110 - - - 22,941 - 58,127 - - - 9,500 10,996 - - - 149,119 (7,356) 498,147 (145) 429 357 - - 1,999 10,591 - - - - - 3,445 3,100 - - - 90,026 (3,503) - - - - 148,720 861,549 65,546 201,288 Fully paid ordinary shares carry one vote per share and carry the right to dividends. Changes to the Companies Act in 1993 abolished the authorised capital and par value concept in relation to share capital from 1 July, 1994. Therefore, the Company does not have a limited amount of authorised capital and issued shares do not have a par value. NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 22. RESERVES Foreign currency translation reserve Balance at beginning of the year Translation of foreign operations Balance at end of the year Group 2014 $’000 (5,675) (24,194) (29,869) 2013 $’000 690 (6,365) (5,675) Exchange differences, principally relating to the translation from Australian dollars, being the functional currency of the Group’s foreign controlled entities in Australia, into New Zealand dollars being the Groups presentation currency, are brought to account by entries made directly to the foreign currency translation reserve. Retained Earnings Balance at beginning of the year Profit for the year Dividends (note 23) Balance at end of the year Cash Flow Hedge Reserve Balance at beginning of the year (Loss)/gain recognised on cash flow hedges Related income tax Balance at end of the year Group 2014 $’000 2013 $’000 Parent 2014 $’000 2013 $’000 107,268 92,069 (52,252) 100,359 28,207 (21,298) 33,623 42,607 (52,252) 20,061 34,860 (21,298) 147,085 107,268 23,978 33,623 1,996 (2,423) 701 274 (418) 2,773 (359) 1,996 1,192 (618) 173 747 (90) 1,532 (250) 1,192 The hedging reserve represents gains and losses recognised on the effective portion of cash flow hedges. The cumulative deferred gain or loss on the hedge is recognised in profit or loss when the hedged transaction impacts profit or loss. 23. DIVIDENDS Recognised amounts Fully paid ordinary shares - Final - prior year - Taxable bonus issue – prior year - Interim - current year Unrecognised amounts Final dividend 2014 Cents per share Total $’000 2013 Cents per share Total $’000 15.0 - 20.5 35.5 21,992 - 30,260 52,252 20.5 - 17.5 38.0 10,682 1,411 9,205 21,298 20.5 30,490 15.0 21,992 A dividend of 20.5 cents per share was declared on 26 August 2014 with the dividend being payable on 17 October 2014. As the dividend reinvestment plan will be in operation for this dividend shareholders may elect to reinvest part or all of their dividends in the Company. The anticipated cash impact of the dividend is approximately $19.5m (2013: $15.0m). EBOS Annual Report 2014 | 31 24. ACQUISITION OF SUBSIDIARIES Name of business acquired Principal activities Date of acquisition Proportion of shares acquired Cost of acquisition $’000 2013: ZHHA Pty Limited (Symbion Group) Healthcare and animal care supplies June 2013 100% 865,000 865,000 Assets and liabilities acquired 2013: Current assets Cash and cash equivalents Trade and other receivables Provision for doubtful debts Prepayments Inventories Other financial assets – derivatives – investment – subordinated notes Non-current assets Property, plant and equipment Deferred tax assets Indefinite life intangibles Finite life intangibles Current liabilities Trade and other payables Finance leases Bank loans Employee benefits Other financial liabilities - derivatives Non-current liabilities Bank loans Trade and other payables Finance leases Employee benefits Deferred tax liabilities Net assets acquired Goodwill on acquisition Consideration Less cash and cash equivalents acquired Deferred purchase consideration Net cash (inflow) on acquisition Symbion Group $’000 Fair value adjustment $’000 Fair value on acquisition $’000 49,263 682,961 (15,329) 4,067 375,709 338 59,541 96,543 27,839 - 27,774 (705,340) (199) (249,097) (15,215) (2,879) (33,405) (4,460) (3,298) (4,531) (4,914) 285,368 - - - - - - (59,541)1 (21,039)2 - 28,8713 69,5223 (7,446)4 - 59,5411 - - - - - - (33,012)5 36,896 49,263 682,961 (15,329) 4,067 375,709 338 - 75,504 27,839 28,871 97,296 (712,786) (199) (189,556) (15,215) (2,879) (33,405) (4,460) (3,298) (4,531) (37,926) 322,264 542,736 865,000 (49,263) (865,000) (49,263) 1. To offset investment in subordinated notes against borrowings, as a result of a difference in accounting policies, resulting in the actual amount owing to the National Australia Bank Limited being recognised as bank loans. 2. Decrease to the value of plant and equipment by $10.1m and a reduction in land and buildings acquired by $10.9m as a result of an independent valuation performed at acquisition. 3. To recognise customer relationships and brands as a result of independent valuations performed at acquisition. 4. Provision to recognise required maintenance and land duty on property acquired as part of the acquisition. 5. Deferred tax resulting from the above fair value adjustments recognised and also to recognise deferred tax on the intangibles of the Symbion Group which were not previously recognised as a result of a difference in accounting policies. NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 24. ACQUISITION OF SUBSIDIARIES continued Goodwill arising on acquisition Goodwill arose in the acquisition of ZHHA Pty Limited (Symbion Group) in 2013 because the cost included a control premium paid. In addition, the consideration paid for the benefit of future expected cashflows above the current fair value of the assets acquired and the expected synergies and future market benefit expected to be obtained. These benefits are not recognised separately from goodwill as the future economic benefits arising from that cannot be reliably measured and they do not meet the definition of identifiable intangible assets. The Symbion Group was acquired as it shares, with EBOS, many of the core competencies required to be successful in a market focused on health professionals, whether that is pharmacists, doctors or veterinarians. The Symbion Group provides the Group with a significant presence in the Australian healthcare and animal care sectors, which may also provide a beachhead for further growth opportunities in these sectors. Impact of acquisition on the results of the Group for 2013 Included in the Group profit for the prior year was $4.687m attributable to the Symbion Group. Had this business combination been effected at 1 July 2012 the revenue of the Group from continuing operations in 2013, inclusive of costs associated with acquisition of subsidiaries, would have been $6,240m and the Group profit for the period from continuing operations would have been $90.0m. 25. NOTES TO THE CASH FLOW STATEMENT (a) Subsidiaries acquired Note 24 sets out details of the subsidiaries acquired. Details of the acquisitions are as follows. Consideration Cash and cash equivalents Shares issued Deferred purchase consideration Represented by: Net assets acquired (Note 24) Investment in subsidiaries Goodwill on acquisition Consideration Net cash outflow/(inflow) on acquisition Cash and cash equivalents consideration Less cash and cash equivalents acquired Group 2014 $’000 2013 $’000 Parent 2014 $’000 2013 $’000 366,853 498,147 (865,000) - - 865,000 235,491 498,147 (865,000) - - 865,000 - - - - - 865,000 (131,362) 865,000 322,264 - 542,736 - (131,362) - - 865,000 - 865,000 (131,362) 865,000 366,853 - - (49,263) 235,491 - 366,853 (49,263) 235,491 - - - On 5 July 2013, in accordance with the sale and purchase agreement to purchase the Symbion Group, the full deferred consideration payable balance of $865m was settled in favour of the previous owners of the Symbion Group, the Zuellig Group. This consideration was made through an issue of EBOS Group Limited shares to the Zuellig Group of $498m and cash consideration of $367m. The cash consideration paid was funded by additional debt funding of $134m and cash reserves. The decrease in Investment in subsidiaries by the Parent company, and the associated consideration, is as a result of the ownership of the subsidiary and related purchase consideration being transferred to another holding company within the Group. EBOS Annual Report 2014 | 33 25. NOTES TO THE CASH FLOW STATEMENT continued (b) Financing facilities Bank overdraft facility, reviewed annually and payable at call: Amount unused Bank loan facilities with various maturity dates through to July 2017 (2013: August 2016): Amount used Amount unused (c) Reconciliation of profit for the year with cash flows from operating activities Profit for the year Add/(less) non-cash items: Depreciation Loss/(gain) on sale of property, plant and equipment Amortisation of finite life intangible assets Share of profits from associates Loss/(gain) on derivatives/financial instruments Deferred tax Provision for doubtful debts Movement in working capital: Trade and other receivables Prepayments Inventories Current tax refundable/payable Trade and other payables Employee benefits Foreign currency translation of working capital balances Cash costs classified as investing activities: Costs associated with acquisition of subsidiaries Working capital items acquired Group 2014 $’000 2013 $’000 Parent 2014 $’000 2013 $’000 1,664 1,664 2,186 2,186 1,250 1,250 1,250 1,250 404,162 407,370 367,032 371,975 89,500 64,800 91,412 64,750 811,532 739,007 154,300 156,162 92,069 28,207 42,607 34,860 10,173 4 12,410 (1,567) 213 (6,366) (531) 14,336 37,684 1,051 66,726 9,386 (69,965) 1,464 (38,599) 7,747 4,922 (170) 1,514 (585) (257) 12 (441) 4,995 (560,276) (3,118) (395,353) (1,503) 621,643 21,832 (6,421) (323,196) - - 5,993 310,416 539 21 - - 213 290 5 1,068 2,177 (103) 234 722 (2,816) (3,719) - (3,505) - - 552 2 - - (257) 279 - 576 (1,456) 739 (32) (389) 6,787 2,802 - 8,451 - - Net cash inflow from operating activities 114,152 26,415 40,170 43,887 NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 26. EARNINGS PER SHARE CALCULATION Basic earnings per share (refer Income Statement and Note 21) Basic earnings per share* Earnings used in the calculation of total basic earnings per share Weighted average number of ordinary shares for the purposes of basic earnings per share Diluted earnings per share (refer Income Statement and Note 21) Diluted earnings per shares* Earnings used in the calculation of total diluted earnings per share Weighted average number of ordinary shares for the purposes of diluted earnings per share Group 2014 Cents 62.8 $’000 2013 Cents 46.8 $’000 92,069 146,681 28,207 60,261 Cents Cents 62.8 $’000 46.8 $’000 92,069 146,681 28,207 60,261 * Earnings per share for the comparative period has been adjusted for the bonus share element included in the rights issue of 5 July 2013, as required by International Financial Reporting Standards. This is to allow a direct like for like comparison of the current period earnings per share with comparative periods. 27. COMMITMENTS FOR EXPENDITURE Capital expenditure commitments Plant Software development 28. CONTINGENT LIABILITIES & CONTINGENT ASSETS Contingent liabilities Guarantees given to third parties Guarantees arising from the deed of cross guarantee with other entities in the wholly-owned group Group 2014 $’000 2013 $’000 Parent 2014 $’000 4,384 138 18,046 802 - - Group 2014 $’000 2013 $’000 Parent 2014 $’000 2013 $’000 - - 2013 $’000 16,613 16,908 529 458 - - 314,660 35,420 On 5 July 2013 all Group debt and securitisation facilities became subject to a new single negative pledge deed to the syndicated banks by the Company and its subsidiaries. The Group’s syndicated bankers from 5 July 2013 to the present are ANZ National Bank Limited, Bank of New Zealand Limited and the National Australia Bank Limited. A subsidiary company (PRNZ Limited) is guarantor for certain loans made to pharmacies by the ANZ National Bank Limited amounting to $5.273m (2013: $5.283m). The directors are of the opinion that provisions are not required in respect of these matters, as it is not probable that a future sacrifice of economic benefits will be required. A performance bond of up to $1m (2013: $1m) is also held by the bank on behalf of a supplier. Property lease guarantees of $8.428m (2013: $9.278m) are held by the bank on behalf of landlords of the Group. EBOS Annual Report 2014 | 35 29. SEGMENT INFORMATION (a) Products and services from which reportable segments derive their revenues The Group’s reportable segments under NZ IFRS 8 are as follows: Healthcare: Incorporates the sale of healthcare products in a range of sectors, own brands, retail healthcare and wholesale activities. Animal care: Incorporates the sale of animal care products in a range of sectors, own brands, retail and wholesale activities. Corporate: Includes net funding costs and parent company central administration expenses that have not been allocated to the healthcare or animal care segments. (b) Segment revenues and results The following is an analysis of the Group’s revenue and results by reportable segment: Revenue from external customers Healthcare Animal care Corporate Profit/(loss) before depreciation, amortisation, finance costs and tax expense Healthcare Animal care Corporate Segment expenses Healthcare: Depreciation Amortisation of finite life intangibles Tax expense Animal care: Depreciation Amortisation of finite life intangibles Tax expense Corporate: Finance costs Tax credit Profit/(loss) for the year Healthcare Animal care Corporate * Includes costs associated with the acquisition of subsidiaries of $5.993m. Associate Information: Included in the Segment results above is Income from Associates of: Animal care Healthcare Group 2014 $’000 2013 $’000 5,418,356 338,878 2,819 5,760,053 1,652,450 169,521 1,198 1,823,169 153,055 29,431 (4,245) 178,241 49,068 18,670 (9,495)* 58,243 (8,693) (10,401) (34,644) (3,785) (1,194) (13,146) (1,480) (2,009) (7,701) (1,137) (320) (4,588) (29,877) 8,633 (9,593) 3,727 99,317 18,241 (25,489) 30,943 12,625 (15,361)* 92,069 28,207 1,433 134 585 - The accounting policies of the reportable segments are consistent with the Group’s accounting policies. Segment result represents profit before depreciation, amortisation, finance costs and tax expense. This is the measure reported to the chief operating decision maker for the purposes of resource allocation and assessment of segment performance. NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 29. SEGMENT INFORMATION continued (c) Segment Assets Assets are not allocated to segments as they are not reported to the chief operating decision maker at a segment level. (d) Revenues from major products and services The Group’s major products and services are the same as the reportable segments i.e. healthcare, animal care and corporate. Revenues are reported above under (b) Segment revenues and results. (e) Geographical information The Group operates in two principal geographical areas; New Zealand (country of domicile) and Australia. The Group’s revenue from external customers by geographical location (of the reportable segment) and information about its segment assets (non-current assets) excluding financial instruments and deferred tax assets are detailed below: Continuing and discontinued operations Revenue from external customers New Zealand Australia Non-current assets New Zealand Australia Group 2014 $’000 2013 $’000 1,279,465 4,480,588 5,760,053 1,257,302 565,867 1,823,169 207,395 753,338 960,733 206,945 765,616 972,561 (f) Information about major customers No revenues from transactions with a single customer amount to 10% or more of the Group’s revenues (June 2013: Nil). 30. RELATED PARTY DISCLOSURES (a) Parent Entities The Parent entity in the Group is EBOS Group Limited. (b) Equity interests in Related Parties Equity interests in subsidiaries Details of the percentage of ordinary shares held in subsidiaries are disclosed in note 15 to the financial statements. (c) Transactions with Related Parties Transactions involving the parent entity Amounts receivable from and (payable to) related parties at balance date are: PRNZ Limited EBOS Group Australia Pty Limited EBOS Shelf Company New Zealand Limited Healthcare Distributors Limited EBOS Health and Science Pty Limited Masterpet Corporation Limited Zuellig Group Incorporated 2014 $’000 2013 $’000 1,174 5,302 (29,319) 348 805 24,042 - - 4,073 (29,319) 348 1,364 28,683 (865,000) 2,352 (859,851) At 30 June 2013 ZHHA Pty Limited owed CB Norwood Pty Limited, a subsidiary of the Zuellig Group, $7.230m and Zuellig Group Incorporated $1.856m. EBOS Group Limited also owed Zuellig Group Incorporated $865m in settlement for the acquisition of the Symbion Group. These balances were repaid during the period. As at 30 June 2014 no balances were owing to related parties of EBOS Group. During the financial year, EBOS Group Limited received dividends of $45.775m (2013: $39.623m) from its subsidiaries. EBOS Annual Report 2014 | 37 30. RELATED PARTY DISCLOSURES continued During the financial year, EBOS Group Limited provided accounting and administration services to its subsidiaries for a consideration of $0.44m (2013: $0.44m) and charged royalties for the use of intellectual property, brand names and patents totalling $2.769m (2013: $3.208m). Terms/price under which related party transactions were entered into All loans advanced to and payable by subsidiaries are unsecured, subordinate to other liabilities and are at call. Interest rates determined by the directors were 0% - 5.6% (2013: 0% - 5%). During the financial year, EBOS Group Limited received interest of $1.159m (2013: $1.155m) from loans to subsidiaries. No amounts were provided for doubtful debts relating to debts due from related parties at reporting date (2013: Nil). Guarantees provided or received As detailed in note 28, EBOS Group Limited has entered into a deed of cross guarantee with certain wholly-owned subsidiaries. (d) Key Management Personnel Remuneration Details of key management personnel remuneration are disclosed in note 4 to the financial statements. 31. FINANCIAL INSTRUMENTS (a) Financial risk management objectives The Group’s corporate treasury function provides services to the Groups entities, co-ordinates access to financial markets, and manages the financial risks relating to the operation of the Group. The Group does not enter into or trade financial instruments, including derivative financial instruments, for speculative purposes. The use of financial derivatives is governed by the Group’s policies approved by the Board of Directors, which provide written principles on the use of financial derivatives. Compliance with policies and exposure limits is reviewed on a regular basis. (b) Market Risk The Group’s activities expose it primarily to the financial risks of changes in foreign currency exchange rates and interest rates. The Group enters into a variety of derivative financial instruments to manage its exposure to interest rate and foreign currency risk, including: • forward foreign exchange contracts to hedge the exchange rate risk arising on imports of product; • interest rate swaps to mitigate the risk of rising interest rates. (c) Foreign currency risk management The Group undertakes certain transactions denominated in foreign currencies, hence exposures to exchange rate fluctuations arise. Exchange rate exposures are managed within approved policy parameters utilising forward foreign exchange contracts. Forward foreign exchange contracts It is the policy of the Group to enter into forward foreign exchange contracts to cover specific foreign currency payments and receipts within 60% to 100% of the exposure generated. The Group also enters into forward foreign exchange contracts to manage the risk associated with anticipated future sales and purchase transactions denominated in foreign currencies. The fair value of forward foreign exchange contracts is determined using a discounted cashflow valuation. Key inputs include the forward exchange rates at the measurement date, with the resulting value discounted back to present values. Therefore the Group has categorised these derivatives as Level 2 under the fair value hierarchy contained within NZ IFRS 13. There were no transfers between fair value hierarchy levels during the current or prior periods. NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 31. FINANCIAL INSTRUMENTS continued Outstanding Contracts 2014 2013 Average exchange rate Foreign currency 2014 FC’000 2013 FC’000 Contract value 2014 $’000 2013 $’000 Fair value 2014 $’000 2013 $’000 Group Buy Australian Dollars Less than 3 months 3 to 6 months 6 to 9 months Buy Euro Less than 3 months 3 to 6 months 6 to 9 months 9 to 12 months Buy Pounds Less than 3 months Buy THB Less than 3 months 3 to 6 months 6 to 9 months Buy US Dollars Less than 3 months 3 to 6 months 6 to 9 months 9 to 12 months 12 to 15 months Sell Australian Dollars Less than 3 months Buy Australian Dollars Less than 3 months Buy Euro Less than 3 months Buy Pounds Less than 3 months Buy US Dollars Less than 3 months Sell Australian Dollars Less than 3 months 0.940 - - 0.650 0.632 0.628 - 0.821 0.823 0.837 0.632 0.638 0.631 0.624 703 - - 2,138 648 648 - 1,214 525 525 1,496 4,020 1,410 2,349 748 - - 3,291 1,025 1,032 - 1,478 638 627 2,368 6,301 2,233 3,763 - 0.557 - 450 - 808 28.355 28.269 28.202 0.832 0.819 0.837 0.836 0.832 - - - 60,000 24,000 24,000 0.824 0.856 0.833 - - 6,415 4,875 4,000 2,500 1,350 - - - 2,356 3,657 800 - - 2,116 849 851 7,709 5,949 4,781 2,990 1,622 - - - 2,860 4,270 960 - - 9 - - 62 1 5 - - (5) 1 4 (373) (331) (140) (68) (14) (46) (19) (8) 150 523 176 287 77 - - - 188 474 87 - - - 0.839 - 105,000 - 125,147 - 885 32,963 151,453 (849) 2,774 Average exchange rate 2014 2013 Foreign currency 2014 FC’000 2013 FC’000 Contract value 2014 $’000 2013 $’000 Fair value 2014 $’000 2013 $’000 Parent 0.941 0.832 400 600 425 721 6 (14) 0.613 0.631 250 250 408 396 (17) - 0.557 - 450 - 808 - 0.842 0.827 1,000 850 1,188 1,028 (42) 25 77 72 - 0.839 - 105,000 - 125,147 - 885 2,021 128,100 (53) 1,045 The fair value of forward foreign exchange contracts outstanding are recognised as other financial assets/liabilities. Hedge accounting is applied for certain forward foreign exchange contracts. Typically these contracts that have hedge accounting applied are for periods greater than 3 months. EBOS Annual Report 2014 | 39 31. FINANCIAL INSTRUMENTS continued (d) Interest rate risk management The Group is exposed to interest rate risk as it borrows funds at floating interest rates. The risk is managed by the use of interest rate swap contracts. Interest rate swap contracts Under interest rate swap contracts, the Group agrees to exchange the difference between fixed and floating rate interest amounts calculated on agreed notional principal amounts. Such contracts enable the Group to mitigate the risk of changing interest rates on debt held. The fair value of interest rate swaps are based on market values of equivalent instruments at the reporting date. Outstanding Contracts Outstanding variable rate for fixed contracts Less than 1 year 1 to 3 years 3 to 5 years Greater than 5 years Outstanding Contracts Outstanding floating for fixed contracts 1 to 3 years 3 to 5 years Greater than 5 years Group Average contracted fixed interest rate Notional principal amount Fair value 2014 % 2013 % 2014 $’000 2013 $’000 2014 $’000 2013 $’000 3.38 3.24 3.77 5.14 5.17 4.68 3.24 - 50,391 113,252 80,402 15,000 90,877 22,424 70,482 - (54) 632 (1,472) (219) (2,168) (555) 621 - 259,045 183,783 (1,113) (2,102) Parent Average contracted fixed interest rate Notional principal amount Fair value 2014 % 2013 % 2014 $’000 2013 $’000 2014 $’000 2013 $’000 3.16 4.64 5.14 - 3.16 - 57,500 15,000 15,000 - 57,500 - 87,500 57,500 1,332 (74) (219) 1,039 - 771 - 771 The fair value of interest rate swaps outstanding are recognised as other financial assets/liabilities. Hedge accounting has been adopted. Interest rate swaps are valued using a discounted cashflow valuation. Key inputs for the valuation of interest rate swaps are the estimated future cash flows based on observable yield curves at the end of the reporting period, discounted at a rate that reflects the credit risk of the various counterparties. Therefore the Group has categorised these derivatives as Level 2 under the fair value hierarchy contained within NZ IFRS 13. There were no transfers between fair value hierarchy levels during the current or prior periods. (e) Liquidity The Group manages liquidity risk by maintaining adequate reserves, banking facilities and reserve banking facilities by continuously monitoring forecast and actual cashflows and matching maturity profiles of financial assets and liabilities. The following tables detail the Group’s remaining contractual maturity for its financial assets and financial liabilities at balance date. The tables have been drawn up based on the undiscounted cash flows of the financial assets and liabilities. The table includes both interest and principal cash flows. NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 31. FINANCIAL INSTRUMENTS continued Group - 2014 Financial assets: Cash and cash equivalents Trade and other receivables Other financial assets - derivatives Financial liabilities: Trade and other payables Finance leases Bank loans Other financial liabilities - derivatives Group - 2013 Financial assets: Cash and cash equivalents Trade and other receivables Other financial assets - derivatives Financial liabilities: Trade and other payables Finance leases Bank loans Other financial liabilities - derivatives - - - 8.6 4.6 - - - - 8.6 4.6 - Weighted average effective interest rate % On Demand $’000 Less than 1 year $’000 1-2 Years $’000 2-3 Years $’000 3-4 Years $’000 4-5 Years $’000 5+ Years $’000 Total $’000 Maturity Dates 2.4 88,698 699,276 - - - 1,442 787,974 1,442 - - - - - - - - - - - - 808,338 - - 13,053 167 37,328 4,349 701 219,825 521 - 98,651 521 - 81,198 - 3,404 - - - 808,338 53,952 224,875 99,172 81,719 - - - - 521 - - - 521 - - - - 88,698 699,276 1,442 789,416 3,646 - - 830,949 868 437,002 - 3,404 3,646 1,272,223 Weighted average effective interest rate % On Demand $’000 Less than 1 year $’000 1-2 Years $’000 2-3 Years $’000 3-4 Years $’000 4-5 Years $’000 5+ Years $’000 Total $’000 Maturity Dates 2.5 198,014 736,429 - - - 3,546 934,443 3,546 - - - - - - - - - - - - 892,124 - - 521 1,504 232,078 5,255 2,841 79,859 521 749 18,068 521 - 61,436 - 2,872 - - - 892,124 236,975 87,955 19,338 61,957 - - - - 521 - - - 521 - - - - 198,014 736,429 3,546 937,989 4,167 - - 903,630 5,094 391,441 - 2,872 4,167 1,303,037 EBOS Annual Report 2014 | 41 31. FINANCIAL INSTRUMENTS continued Parent - 2014 Financial assets: Cash and cash equivalents Trade and other receivables Other financial assets Advances to subsidiaries Financial liabilities: Trade and other payables Bank loans Other financial liabilities Advances from subsidiaries Parent - 2013 Financial assets: Cash and cash equivalents Trade and other receivables Other financial assets Advances to subsidiaries Financial liabilities: Trade and other payables Bank loans Advances from subsidiaries Weighted average effective interest rate % On Demand $’000 Less than 1 year $’000 1-2 Years $’000 2-3 Years $’000 3-4 Years $’000 4-5 Years $’000 5+ Years $’000 Total $’000 Maturity Dates 3.3 - - 3.8 - 5.2 - - 4,075 8,217 - - - - 1,337 32,860 12,292 34,197 - - - - - - - - - - - - - - - 6,356 - - - - 8,597 352 29,319 - 29,254 - - - 31,684 - - - 29,508 - - 6,356 38,268 29,254 31,684 29,508 Maturity Dates - - - - - - - - - - - - - - - - - - - - 4,075 8,217 1,337 32,860 46,489 6,356 99,043 352 29,319 135,070 Weighted average effective interest rate % On Demand $’000 Less than 1 year $’000 1-2 Years $’000 2-3 Years $’000 3-4 Years $’000 4-5 Years $’000 5+ Years $’000 Total $’000 2.5 - - 3.8 - 4.5 - - 89,305 10,399 - - - - 1,816 35,769 99,704 37,585 - - - - - - - - - - - - - - - 9,172 - - - 8,045 29,319 - 58,155 - 9,172 37,364 58,155 - 5,316 - 5,316 - 27,155 - 27,155 - - - - - - - - - - - - - - - - - - 89,305 10,399 1,816 35,769 137,289 9,172 98,671 29,319 137,162 As at 30 June 2014 the Group maintained the following lines of credit: Facility Amount (NZD) Maturity Term debt facilities Term debt facilities Term debt facilities Working capital facilities Securitisation facility $75.3m $94.3m $100.2m $90.5m $450.3m July 2015 July 2016 July 2017 July 2015 September 2015 At 30 June 2013 the Group’s lines of credit included $2.2m overdraft facilities and term loan facilities of $123 million maturing in August 2014 and of $119 million maturing in August 2016. Please refer to note 17 for details of the Group’s securitisation, working capital and term debt facilities subsequent to 30 June 2014. NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 31. FINANCIAL INSTRUMENTS continued (f) Sensitivity Analysis (i) Interest Rate Sensitivity Analysis The sensitivity analysis below has been determined based on the exposure to interest rates for financial instruments at the balance date. The analysis is prepared assuming the amount of the financial instrument outstanding at the balance sheet date was outstanding for the whole year. The impact to Profit for the Year and Total Equity as a result of a 100 basis point movement in interest rates is as follows: + 100 basis point shift up in yield curve Impact on Profit Impact on Total Equity - 100 basis point shift down in yield curve Impact on Profit Impact on Total Equity (ii) Foreign Currency Sensitivity Analysis Group 2014 $’000 - 5,620 2013 $’000 - 3,142 Parent 2014 $’000 - 2,231 2013 $’000 - 1,626 - (5,863) - (3,249) - (2,326) - (1,692) The following table details the Group’s sensitivity to a 10% increase or decrease in the foreign currency rate against the functional currency of the Company or a subsidiary of the Group. The sensitivity analysis below is determined on exposure to outstanding foreign currency contracts and foreign currency monetary items, and adjusts their translation at the year end for a 10% change in foreign currency rates. A positive number below indicates an increase in profit and equity where the functional currency weakens 10% against the relevant currency. + 10% shift in NZD rate Impact on Profit for the Year Impact on Total Equity - 10% shift in NZD rate Impact on Profit for the Year Impact on Total Equity (g) Credit Risk Management Group 2014 $’000 2013 $’000 Parent 2014 $’000 2013 $’000 (196) (3,138) (283) 8,733 (196) (196) (283) 11,010 196 3,173 346 (10,668) 196 196 346 (13,457) Credit risk refers to the risk that a counter party will default on its contractual obligations resulting in financial loss to the Group. The Group has adopted a policy of only dealing with credit worthy counter parties and obtaining sufficient collateral where appropriate, as a means of mitigating the risk of financial loss from defaults. Trade receivables consist of a large number of customers, spread across diverse sectors and geographical areas. Ongoing credit evaluation is performed on the financial condition of the trade receivables. The carrying amount of financial assets recorded in the financial statements, net of any allowances for losses, represents the Group’s maximum exposure to credit risk without taking account of the value of any collateral obtained. The maximum credit risk associated with guarantees provided by the Group and Parent are disclosed in note 28. The Group does not have any significant credit risk exposure to any single counter party or any Group of counter parties having similar characteristics. The credit risk on liquid funds and derivative financial instruments is limited because the counter parties are banks with high credit ratings assigned by international credit rating agencies. EBOS Annual Report 2014 | 43 31. FINANCIAL INSTRUMENTS continued (h) Fair value of financial instruments The Directors consider that the carrying amount of financial assets and financial liabilities recorded in the financial statements approximates their fair values. The fair values and net fair values of financial assets and financial liabilities are determined as follows: • the fair value of financial assets and financial liabilities with standard terms and conditions and traded on active liquid markets are determined with reference to quoted market prices; • the fair value of other financial assets and financial liabilities are determined in accordance with generally accepted pricing models based on discounted cash flow analysis; and • the fair value of derivative instruments are calculated using quoted prices. Where such prices are not available use is made of discounted cash flow analysis using the applicable yield curve for the duration of the instruments. (i) Liquidity risk management The Group manages liquidity risk by maintaining adequate reserves, banking facilities and reserve borrowing facilities by continuously monitoring forecast and actual cash flows and matching the maturity profiles of financial assets and liabilities. (j) Capital Risk Management The Group manages its capital, meaning Total Shareholders’ Funds, to ensure that each entity within the Group will be able to continue as a going concern while maximising the return to stakeholders through the optimisation of the debt and equity. The Group has certain capital risk management covenants under its negative pledge agreement with its bankers, such as retaining minimum shareholder funds. None of its banking covenants were breached during the year. The Group’s overall strategy remains unchanged from 2013. 32. EVENTS AFTER BALANCE DATE Subsequent to year end the Board has approved a final dividend to shareholders. For further details please refer to note 23. Subsequent to year end the Group has renegotiated some of the terms and conditions of its term debt and securitisation facilities, please refer to note 17. NOTES TO THE FINANCIAL STATEMENTS continuedFor the Financial Year ended 30 June, 2014 EBOS Annual Report 2014 ADDITIONAL STOCK EXCHANGE INFORMATION As at 31 July 2014 Twenty Largest Shareholders Sybos Holdings Pte Limited HSBC Nominees (New Zealand) Limited – NZCSD Whyte Adder No 3 Limited JP Morgan Chase Bank – NZCSD Sybos Holdings Pte Limited * Tea Custodians Limited – NZCSD Accident Compensation Corporation – NZCSD Custodial Services Limited Forsyth Barr Custodians Limited <1-33> National Nominees New Zealand Limited – NZCSD Citibank Nominees (New Zealand) Limited – NZCSD FNZ Custodians Limited HSBC Nominees (New Zealand) Limited – NZCSD New Zealand Superannuation Fund Nominees Limited – NZCSD Herpa Properties Limited BNP Paribas Nominees (NZ) Limited – NZCSD Custodial Services Limited Custodial Services Limited Forsyth Barr Custodians Limited <1-17.5> Custodial Services Limited * 4,667,445 shares are held in escrow until 5 January 2015. Substantial Security Holders Fully paid shares Percentage of paid capital 54,820,491 8,780,963 6,993,234 4,966,896 4,667,445 3,784,862 2,754,994 2,745,360 2,139,731 2,069,144 1,961,258 1,813,771 1,678,674 1,435,068 1,324,551 1,185,874 997,344 891,244 820,242 772,063 106,603,209 36.86% 5.90% 4.70% 3.34% 3.14% 2.54% 1.85% 1.85% 1.44% 1.39% 1.32% 1.22% 1.13% 0.97% 0.89% 0.80% 0.67% 0.60% 0.55% 0.52% 71.68% As at 31 July 2014 the following persons are deemed to be substantial security holders in accordance with Section 26 of the Securities Markets Amendment Act 1988. Sybos Holdings Pte Limited** Fidelity Holdings Whyte Adder No 3 Limited & Herpa Properties Limited ** 58,126,842 shares are held in escrow until 26 August 2014. Fully paid shares Percentage of paid capital 59,487,936 14,046,855 8,317,785 81,852,576 40.00% 9.45% 5.59% 55.04% Distribution of Shareholders and Shareholdings Holders Fully paid shares Percentage of paid capital Size of Holding 1 to 999 1,000 to 4,999 5,000 to 9,999 10,000 to 49,999 50,000 to 99,999 100,000 to 499,999 500,000 to 999,999 1,000,000 and over Total Registered Address of Shareholders New Zealand Overseas Total 322 4,508 944 775 52 25 12 16 6,654 14,712 8,360,414 6,485,820 14,230,290 3,414,996 4,689,593 8,401,698 103,122,316 148,719,839 6,360 294 6,654 84,222,039 64,497,800 148,719,839 0.01% 5.62% 4.36% 9.57% 2.30% 3.15% 5.65% 69.34% 100.00% 56.63% 43.37% 100.00% EBOS Annual Report 2014 | 45 BOARD OF DIRECTORS RICK CHRISTIE MSC (HONS), FNZIoD Independent Chairman of Directors Joined the EBOS Group Limited Board in June 2000 and was appointed Chairman in April 2003. He is a member of the Audit and Risk Committee, and Chairman of the Remuneration Committee and the Nomination Committee. Rick Christie is a professional director with a breadth of governance and international management experience in a number of industries. He is the Chairman of ikeGPS Group Ltd, National e-Science Infrastructure – NeSI, and Service IQ and a director of South Port New Zealand Limited, Solnet Solutions Limited, and Acurity Health Group Limited. He is also a Companion of The Royal Society of New Zealand, a former director of Television New Zealand and the New Zealand Symphony Orchestra and a past president of Chamber Music New Zealand. He was previously Chairman of AgResearch Limited, Deputy Chairman of the Foundation for Research, Science & Technology and Chairman of the Victoria University Foundation Board of Trustees and a former Chief Executive of the diversified investment company Rangatira Limited, a former Managing Director of Cable Price Downer and former Chief Executive of Trade New Zealand. MARK WALLER BCOM, FACA, FNZIM Executive Director STUART McGREGOR BCOM, LLB, MBA SARAH OTTREY BCOM Independent Director Mark Waller has been Chief Executive and Managing Director of EBOS Group Limited from 1987 to 30 June 2014. He is a member of the Remuneration Committee. He is a director of all the EBOS Group Limited subsidiaries, as well as being a director of Scott Technology Limited and HTS-110 Limited (alternate director). He was the recipient of the Leadership Award in May 2014 INFINZ Industry Awards. Appointed to the EBOS Group Limited Board in September 2006. Sarah Ottrey is a director of Comvita Limited, Whitestone Cheese Limited and Sarah Ottrey Marketing Limited, and is a member of the Audit and Assurance Committee Inland Revenue. She is a past board member of Blue Sky Meats (NZ) Limited, the Public Trust and the Smiths City Group. Sarah has held senior marketing management positions with Unilever and Heineken. Stuart McGregor was appointed to the EBOS Group Limited Board in July 2013. Stuart was educated at Melbourne University and the London School of Business Administration, gaining degrees in Commerce and Law. He also completed a Masters of Business Administration. Currently Stuart is Chairman of Donaco International Ltd, an ASX listed company. He is also Chairman of Powerlift Australia Pty Ltd, and C B Norwood Pty Ltd and director of Symbion Pty Ltd. Over the last 30 years, Stuart has been Company Secretary of Carlton and United Breweries, Managing Director of Cascade Brewery Company Limited in Tasmania and Managing Director of San Miguel Brewery Hong Kong Limited. In the public sector, he served as Chief of Staff to a Minister for Industry and Commerce in the Federal Government and as Chief Executive of the Tasmanian Government’s Economic Development Agency. EBOS Annual Report 2014 BARRY WALLACE MCOM (HONS), CA PETER KRAUS MA (HONS), DIP ENG. ELIZABETH COUTTS BMS, CA Independent Director PETER WILLIAMS Peter Kraus has been a Director of EBOS Group Limited since 1990. He is a member of the Nomination Committee. He is a director of Whyte Adder No 3 Limited, Strand Holdings Limited, Herpa Properties Limited, Ecostore Company Limited, Huckleberry Farms Limited, and Peton Villas Limited. Barry Wallace was appointed to the EBOS Group Limited Board in October 2001. He is Chairman of the Audit and Risk Committee and member of the Remuneration Committee. Barry is a chartered accountant with a background in financial management. He is a director of Allum Management Services Ltd, Whyte Adder No 3 Limited, Strand Holdings Limited, Herpa Properties Limited, Ecostore Company Limited, Huckleberry Farms Limited, and Peton Villas Limited. He is a former Chief Executive of Health Support Limited and is the Finance Director of a private group of companies and trusts. Elizabeth Coutts was appointed to the EBOS Group Limited Board in July 2003. She is a member of the Audit and Risk Committee and the Nomination Committee. She is Chair of Urwin & Co Limited, and director of NZ Directories Holdings Ltd (and subsidiaries), Ports of Auckland Limited, Ravensdown Feteriliser Co-operative Limited, Sanford Limited, Skellerup Holdings Limited and Tennis Auckland Region Incorporated, and member, Marsh New Zealand Advisory Board. She is Chair of the Inland Revenue Risk and Assurance Committee, Chair Auckland Branch and National Council member of Institute of Directors Inc. Elizabeth is a former Chairman of Meritec Group, Industrial Research, and Life Pharmacy Limited, former director of Air New Zealand Limited and the Health Funding Authority, former Deputy Chairman of Public Trust, former board member of Sport NZ, former member of the Pharmaceutical Management Agency (Pharmac), former Commissioner for both the Commerce and Earthquake Commissions, former external monetary policy adviser to the Governor of the Reserve Bank of New Zealand and former Chief Executive of the Caxton Group of Companies. Peter Williams was appointed to the EBOS Group Limited Board in July 2013. Peter has been an executive of the Zuellig Group since 2000. Peter is a director of Interpharma Investments Limited, Asia’s leading distributor of healthcare products, and of Pharma Industries Limited. He is also a director of Cambert, a company marketing health and personal care products in South East Asia. EBOS Annual Report 2014 | 47 CORPORATE GOVERNANCE STATEMENT The Board and management of EBOS Group Limited are committed to ensuring that the Company adheres to best practice and governance principles and maintains high ethical standards. The Board has agreed to regularly review and assess the Company’s governance structures to ensure they are consistent, both in form and in substance, with best practice. The Board considers that the Company’s Corporate Governance policies, practices and procedures substantially comply with the New Zealand Exchange Corporate Governance Best Practice Code. The Company further supports the ASX Corporate Governance Council’s Corporate Governance Principles and Recommendations (“ASX Principles”). Further information on the Company’s corporate governance policies and practice can be found in the Company’s Corporate Governance Code, the full content of which can be found on the Company’s website (www.ebosgroup.com). PRINCIPLE 1: LAY SOLID FOUNDATIONS FOR MANAGEMENT AND OVERSIGHT PRINCIPLE 2: STRUCTURE THE BOARD TO ADD VALUE Role of the Board and Management Board Composition The Board is responsible for the direction and supervision of the business and affairs of the Company and the monitoring of the performance of the Company on behalf of shareholders. The Board also places emphasis on regulatory compliance. Responsibility for the day to day management of the Company has been delegated to the Chief Executive and his management team. The Board is responsible for directing the Company and enhancing its value for shareholders. It has adopted a formal Corporate Governance Code which details the Board’s responsibilities, membership and operation. A copy of the Code is available at the Company’s website at www.ebosgroup.com. As part of the Board’s oversight of senior management, all Company executives are subject to annual performance review and goal planning. In addition, the Board monitors the performance of the CEO against the Board’s requirements and expectations. In the 12 month period ending 30 June 2014, a report on the performance of each member of the Company’s senior management was completed, and the report was discussed with the executive concerned as part of the annual review process for that executive. The Board is structured to bring to its deliberations a range of experience relevant to the Company’s operations. Pages 46 to 47 set out the qualifications, expertise and experience of each Director in office as at the date of this report. The Board is elected by the shareholders of EBOS Group Limited. At each annual meeting at least one third of the directors retire by rotation. The Board currently comprises eight directors, three of which are considered to be independent as that term is defined in the NZX Main Board Listing Rules, the ASX Listing Rules and the ASX Principles. The following are non-executive directors: Chairman, Rick Christie; Elizabeth Coutts; Peter Kraus; Stuart McGregor; Sarah Ottrey; Barry Wallace and Peter Williams. The Company has one executive director Mark Waller. Rick Christie, Elizabeth Coutts and Sarah Ottrey have been determined as Independent Directors. The Board believes that its current structure is appropriate. Peter Kraus has had a long and substantial involvement with the Company, with interests associated with him having significant equity interests in the Company. The involvement of Peter Williams and Stuart McGregor reflects the confidence of Sybos Holdings Pte Limited as a 40% shareholder in the Company. A further enlargement of the Board for the sole purpose of complying with the ASX Principles is not justified as this time given the calibre of the current Board. Board Committees Specific responsibilities are delegated to the Audit and Risk Committee, the Remuneration Committee and the Nomination Committee. Each of these committees has a charter setting out the committee’s objectives, procedures, composition and responsibilities. Copies of these charters are available on the Company’s website. Board Processes The table at page 51 shows attendances at the Board and Committee meetings during the year ended 30 June 2014. Under the Company’s Corporate Governance Code, the Chairman is responsible for the processes for evaluating the performance of the Board, Board Committees and individual directors. The Company’s Corporate Governance Code provides for directors of the Company to obtain independent professional advice at the expense of the Company subject to the obtaining of the prior approval of the Audit and Risk Committee to do so. Share Trading by Directors and Officers The Company has formal procedures that directors and officers must follow when trading EBOS shares. They must notify and obtain the consent of the Chairman prior to any trading. Remuneration Committee The Remuneration Committee provides the Board with assistance in establishing relevant remuneration policies and practices for directors, executives and employees. Members of the Remuneration Committee are Rick Christie (Chairman), Barry Wallace and Mark Waller. Nomination Committee The procedure for the appointment and removal of directors is ultimately governed by the Company’s Constitution. A director is appointed by ordinary resolution of the shareholders although the Board may fill a casual vacancy. The Board has delegated to the Nomination Committee the responsibility for recommending candidates to be nominated as a director on the Board and candidates for the committees. When recommending candidates to act as a director, the Nomination Committee takes into account such factors as it deems appropriate, including the experience and qualifications of the candidate. The current members of the Nomination Committee are Rick Christie (Chairman), Elizabeth Coutts and Peter Kraus. The majority of the EBOS Annual Report 2014 members of the Nomination Committee are independent. and procedures relating to risk oversight, identification, management and control. The Nomination Committee Charter which outlines the Committee’s authority, duties, responsibility and relationship with the Board is set out as Appendix D to the Code and is available on the Company’s website. PRINCIPLE 3: PROMOTE ETHICAL AND RESPONSIBLE DECISION MAKING The Board has a code of conduct in the form of its Code of Ethics. The Code of Ethics is set out as Appendix A to the Code and is available on the Company’s website. The Code of Ethics is the framework of standards by which the directors and employees of EBOS and its related companies are expected to conduct their professional lives, and covers conflicts of interest, receipt of gifts, confidentiality, expected behaviour, delegated authority and compliance with laws and policies. The NZX Main Board Listing Rules, until recently, have not required companies to have diversity policies and, as a result, the Company has yet to adopt a formal policy concerning diversity. However, the Board is committed to the establishment and maintenance of appropriate ethical standards and in its recruitment practices is committed to recruiting individuals with the appropriate skills and qualifications required for the role. The Board intends to implement a formal diversity policy in accordance with the Principles and will at that point implement measurable objectives for achieving gender diversity. Members of the Audit and Risk Committee are Barry Wallace (Chairman), Rick Christie and Elizabeth Coutts. Despite not being an independent director, the Board considers Barry Wallace to be an appropriate director to chair the Audit and Risk Committee given his qualifications as a chartered accountant and his background in financial management. The Audit and Risk Committee Charter which outlines the Committee’s authority, duties, responsibility and relationship with the Board is set out as Appendix B to the Code and is available on the Company’s website. Information on the procedures for the selection and appointment of the external auditor, and for the rotation of external audit engagement partners, is set out in section 9 of the Code. PRINCIPLE 5: MAKE TIMELY AND BALANCED DISCLOSURE The Company has a written policy which is designed to ensure compliance with the NZX Main Board Listing Rule disclosure requirements and to ensure accountability at a senior executive level for that compliance. The General Counsel is responsible for the Company’s compliance with statutory and NZX continuous disclosure requirements and the Board is advised of, and consider, continuous disclosure issues at each Board meeting. The Company intends to amend the Code in due course to reflect that the Company is also required to comply with ASX Listing Rule requirements. The Code is available on the Company’s website. The Company’s gender representation is as follows: PRINCIPLE 6: RESPECT THE RIGHTS OF SHAREHOLDERS Female % Male % Board Executive 25 7 75 93 PRINCIPLE 4: SAFEGUARD INTEGRITY IN FINANCIAL REPORTING The Audit and Risk Committee provides the Board with assistance in fulfilling its responsibilities to shareholders, the investment community and others for overseeing the Company’s financial statements, financial reporting processes, internal accounting systems, financial controls, internal audit and annual external financial audit and EBOS’s relationship with its internal auditor and external auditor. In addition, the Audit and Risk Committee is responsible for the establishment of policies Respecting the rights of shareholders is of fundamental importance to the Company and a key element of this is how the Company communicates to its shareholders. To this end, the Company recognises that shareholders must receive relevant information in a timely manner in order to be able to properly and effectively exercise their rights as shareholders. Information is communicated to shareholders in the Annual Report and the Interim Report. The Board has adopted a policy of Continuous Disclosure that complies with the NZSX Listing Rules. The Board encourages full participation of shareholders at the Annual Meeting to ensure a high level of accountability and identification with the Group’s strategies and goals. Investors can obtain information on the Company from its website (www.ebosgroup.com). The site contains recent NZSX and ASX announcements and reports. The Company has developed a set of shareholder participation principles which are designed to promote effective communication with shareholders and encourage shareholder participation at general meetings. These principles are set out in section 12 of the Code. PRINCIPLE 7: RECOGNISE AND MANAGE RISK The Company has established an Audit and Risk Committee whose purpose is to, among other things, assist the Board in discharging its responsibility to exercise due care, diligence and skill in relation to identifying and monitoring material business risks. A summary of the functions of the Audit and Risk Committee is set out in the Audit and Risk Committee Charter which is available on the Company’s website. The management team reports to the Board and/or the Audit and Risk Committee on whether the Company’s material business risks are being managed effectively. For the annual and half-year accounts released publicly, the Board has received assurance from the Chief Executive Officer and the Chief Financial Officer that, in their opinion, the financial records of the Company have been properly maintained; the financial statements and notes required by accounting standards for external reporting give a true and fair view of the financial position and performance of the Company and the consolidated group, and comply with the accounting standards, any further requirements in legislation and applicable ASIC Class Order, and the representations are based on a sound system of risk management and internal control and that the system is operating effectively in all material respects in relation to financial reporting risks. PRINCIPLE 8: REMUNERATE FAIRLY AND RESPONSIBLY The Company has established a Remuneration Committee, the current members of which are Rick Christie, Barry Wallace and Mark Waller. The Remuneration Committee’s Charter which outlines the Committee’s authority, duties, responsibility and relationship with the board is set out as Appendix C to the Code and is available on the Company’s website. The Committee does not comprise a majority of independent directors. Barry Wallace and Mark Waller are not independent directors. EBOS Annual Report 2014 | 49 Page 48 to 49 set out the details of the Company’s policy and practices for remunerating directors and senior executives. WAIVERS FROM THE NZX AND ASX LISTING RULES Waivers granted from the application of NZX and ASX Listing Rules are published on the Company’s website. VOTING RIGHTS Shareholders may vote at a meeting of shareholders either in person or by Proxy, Attorney, or Representative. Where voting is by show of hands or by voice every shareholder present in person or representative has one vote. In a poll every shareholder present in person or by representative has one vote for each share. USE OF CASH AND CASH EQUIVALENTS In accordance with ASX Listing Rule 4.10.19 the Board has determined that the Company has used cash and cash equivalents that it had at the time of its admission to the ASX in a way consistent with its business objectives from the period of its admission to the ASX on 3 December 2013 to 30 June 2014. ANNUAL GENERAL MEETING The Annual General Meeting of Shareholders will be held at the Great Hall, Chateau on the Park, Cnr Deans Avenue and Kilmarnock Street, Riccarton, Christchurch, New Zealand at 2pm on Friday 31 October 2014. DIRECTORS’ INTERESTS Share dealings by Directors The Directors have disclosed to the Board under section 148(2) of the Companies Act 1993 particulars of acquisitions of dispositions of relevant interest. Disclosure of interests by Directors In accordance with section 140(2) of the Companies Act 1993, the directors named below have made general disclosure of interest, by a general notice disclosed to the Board and entered in the Company’s interest register, as follows: R.G.M. Christie: Chairman of ikeGPS Group Ltd, National e-Science Infrastructure – NeSI, and Service IQ. Director of South Port New Zealand Ltd, Solnet Solutions Ltd, and Acurity Health Group Ltd. E.M. Coutts: Chair of Urwin & Co Ltd, and Director of NZ Directories Holdings Ltd (and subsidiaries), Ports of Auckland Ltd, Director of Ravensdown Fertiliser Co- operative Limited, Sanford Ltd, Skellerup Holdings Ltd and Tennis Auckland Region Incorporated, and Member, Marsh New Zealand Advisory Board and Chair of Inland Revenue, Risk and Assurance Committee, Chair Auckland Branch and National Council member of Institute of Directors Inc. P.F. Kraus: Director of Whyte Adder No.3 Ltd, Strand Holdings Ltd, Herpa Properties Ltd, Ecostore Company Ltd, Huckleberry Farms Ltd, and Peton Villas Ltd. S.J. McGregor: Chairman of Donaco International Ltd, Powerlift Australia Pty Ltd; C.B. Norwood Pty Ltd and director of Symbion Pty Ltd. S.C. Ottrey: Director of Blue Sky Meats (NZ) Ltd, Comvita Ltd, Whitestone Cheese Ltd, and Sarah Ottrey Marketing Ltd and Member of the Audit and Assurance Committee Inland Revenue. B.J. Wallace: Director of Allum Management Services Ltd, Whyte Adder No 3 Ltd, Strand Holdings Ltd, Herpa Properties Ltd, Ecostore Company Ltd, Huckleberry Farms Ltd, and Peton Villas Ltd. M.B. Waller: Director of EBOS Group Ltd (and its associated companies), Scott Technology Ltd, and HTS-110 Ltd (Alternate Director). P.J. Williams: Executive of The Zuellig Group and associated companies, a director of Interpharma Investments Ltd, Pharma Industries Ltd and Cambert. EBOS Annual Report 2014 DIRECTORS’ DISCLOSURES There were no notices from directors of the Company requesting to use company information received in their capacity as directors, which would not otherwise have been available to them. SHARE DEALINGS BY DIRECTORS Director R G M Christie – All non-beneficially held E M Coutts – Held by associated persons S C Ottrey – Held by associated persons P F Kraus P F Kraus – Held by associated persons B J Wallace – non beneficially held M B Waller – Held by associated persons Non beneficially held M B Waller – Non-beneficially held DIRECTORS’ SHAREHOLDINGS Ordinary Shares Purchased/(Sold) Consideration Paid/(Received) (20,550) 8,896 324 431 2,036 94 125 418 2,196,918 101,815 135,589 2,196,918 101,815 135,689 81,898 – 14 (20,550) – $57,824 $3,090 $4,276 $13,234 $895 $1,244 $2,717 $14,279,967 $969,982 $1,342,346 $14,279,967 $969,982 $1,342,346 $532,337 ($210,000) $144 – Date of Transaction June 2014 July 2013 October 2013 April 2014 July 2013 October 2013 April 2014 July 2013 July 2013 October 2013 April 2014 July 2013 October 2013 April 2014 July 2013 July 2013 April 2014 June 2014 Number of fully paid shares held as at 30 June 2014 30 June 2013 E M Coutts R G M Christie P F Kraus S C Ottrey B J Wallace M B Waller ATTENDANCE R Christie P Kraus E Coutts S Ottrey S McGregor B Wallace M Waller P Williams – Held by associated persons – Non beneficially held – Staff share purchase scheme – Held by associated persons – Held by associated persons – Non beneficially held – Director of Whyte Adder No.3 Ltd/Herpa Properties Ltd – Held by associated persons – Non beneficially held – Staff share purchase scheme 26,497 125,092 1,535 8,317,785 7,705 8,317,785 530,191 125,092 26,497 145,642 1,535 8,317,785 7,705 8,317,785 530,191 145,642 Board Audit & Risk Eligible to Attend Attended Eligible to Attend Attended Remuneration Eligible to Attend Attended 8 8 8 8 8 8 8 8 8 3 8 4 8 8 8 7 5 - 5 - - 5 5 - 5 - 5 - - 5 4 - 3 - - - - 3 3 - 3 - - - - 3 3 - EBOS Annual Report 2014 | 51 INDEMNITY AND INSURANCE In accordance with section 162 of the Companies Act 1993 and the constitution of the Company, the company has given indemnities to, and has effected insurance for, the directors and executives of the Company and its related companies which, except for some specific matters which are expressly excluded, indemnify and insure directors and executives against monetary losses as a result of actions undertaken by them in the course of their duties. Specifically excluded are certain matters, such as the incurring of penalties and fines, which may be imposed for breaches of law. DIRECTORS’ REMUNERATION AND OTHER BENEFITS Directors’ remuneration and other benefits required to be disclosed pursuant to section 211(1) of the Companies Act 1993 for the year ended 30 June 2014 were as follows: R.G.M. Christie E.M. Coutts P.F. Kraus S J McGregor (appointed 5/7/13) S.C. Ottrey B.J. Wallace P J Williams (appointed 5/7/13) M.B. Waller (Chief Executive and Managing Director) 30 June 2014 30 June 2013 $215,000 $110,000 $100,000 $100,000 $100,000 $118,000 $100,000 $154,000 $106,500 $70,500 - $70,500 $123,500 - Salary * Other benefits $1,773,000 $1,702,720 $494,884 $1,684,556 * Includes a one off long term incentive; performance bonus and other emoluments. EMPLOYEE REMUNERATION Grouped below, in accordance with Section 211 of the Companies Act 1993, are the number of employees or former employees of the company and its subsidiaries, including those based in Australia, who received remuneration and other benefits in their capacity as employees totalling NZ$100,000 or more during the year. Employee Remuneration (NZ$) 30 June 2014 Number of Employees 30 June 2013 Number of Employees 100,000 – 110,000 110,000 – 120,000 120,000 – 130,000 130,000 – 140,000 140,000 – 150,000 150,000 – 160,000 160,000 – 170,000 170,000 – 180,000 180,000 – 190,000 190,000 – 200,000 200,000 – 210,000 210,000 – 220,000 220,000 – 230,000 230,000 – 240,000 240,000 – 250,000 250,000 – 260,000 260,000 – 270,000 270,000 – 280,000 280,000 – 290,000 290,000 – 300,000 300,000 – 310,000 310,000 – 320,000 320,000 – 330,000 330,000 – 340,000 340,000 – 350,000 41 54 38 14 27 21 20 15 1 9 5 9 3 4 1 2 3 1 3 4 2 1 2 1 1 27 22 15 3 9 7 7 3 1 5 3 2 1 1 1 1 1 3 - - - - - - 1 EBOS Annual Report 2014 Employee Remuneration (NZ$) 30 June 2014 Number of Employees 30 June 2013 Number of Employees 350,000 – 360,000 360,000 – 370,000 370,000 – 380,000 380,000 – 390,000 410,000 – 420,000 450,000 – 460,000 520,000 – 530,000 550,000 – 560,000 590,000 – 600,000 600,000 – 610,000 610,000 – 620,000 630,000 – 640,000 680,000 – 690,000 720,000 – 730,000 780,000 – 790,000 790,000 – 800,000 820,000 – 830,000 830,000 – 840,000 840,000 – 850,000 920,000 – 930,000 1,430,000 – 1,440,000 AUDITOR 1 1 1 1 1 1 1 - - 1 1 1 1 1 1 - 1 2 - 1 1 - - - 1 1 - - 1 1 - - - - - - 1 - - 1 - - The Company’s Auditor, Deloitte, will continue in office in accordance with the Companies Act 1993. The Directors are satisfied that the provision of non-audit services, during the year by the auditor is compatible with the general standard of independence for auditors imposed by the Companies Act 1993. Details of amounts paid or payable to the auditor for non-audit services provided during the year by the auditor are outlined in note 5 to the financial statements. R.G.M. Christie Chairman of Directors M.B. Waller Director EBOS Annual Report 2014 | 53 DIRECTORY CORPORATE HEAD OFFICE DIRECTORS SENIOR EXECUTIVES Rick Christie Independent Chairman Patrick Davies Chief Executive Officer Mark Waller Executive Director Brett Barons Elizabeth Coutts Independent Director General Manager, Symbion Pharmacy Peter Kraus Stuart McGregor Sarah Ottrey Independent Director Barry Wallace Peter Williams Michael Broome Group General Manager, Simon Bunde ProPharma & HCL General Manager, Group Operations & Strategy Angus Cooper General Manager, Group Projects, Mergers & Acquisitions John Cullity Chief Financial Officer Sean Duggan Chief Executive Officer, Animal Care Tim Goldenberg Group Human Resources Manager Kelvin Hyland General Manager, EBOS Healthcare David Lewis Greg Managh General Manager, EBOS Healthcare Australia Group Chief Information Officer Stuart Spencer General Manager, Group Business Development Sarah Turner General Counsel Andrew Vidler General Manager, Retail Services 108 Wrights Road PO Box 411 Christchurch 8024 New Zealand Telephone +64 3 338 0999 Fax +64 3 339 5111 Email: ebos@ebosgroup.com Internet: www.ebosgroup.com AUSTRALIA HEAD OFFICE Level 3, 484 St Kilda Road PO Box 7300 Melbourne 3004 Australia Telephone +61 3 9918 5555 AUDITOR Deloitte Christchurch BANKERS ANZ New Zealand Limited Auckland Bank of New Zealand Christchurch Australia and New Zealand Banking Group Limited Melbourne National Australia Bank Limited Sydney SOLICITOR Chapman Tripp Christchurch SHARE REGISTER Computershare Investor Services Ltd Private Bag 92119 Auckland 1142 159 Hurstmere Road Takapuna, North Shore City 0622 New Zealand Telephone +64 9 488 8777 Computershare Investor Services Pty Ltd GPO Box 3329 Melbourne, Victoria 3001 Australia Telephone: 1800 501 366 EBOS Annual Report 2014 Managing Your Shareholding Online: To change your address, update your payment instructions and to view your investment portfolio including transactions, please visit: www.computershare.com/investorcentre General enquiries can be directed to: • enquiry@computershare.co.nz • Private Bag 92119, Auckland 1142, New Zealand or GPO Box 3329, Melbourne, Victoria 3001, Australia • Telephone (NZ) +64 9 488 8777 or (Aust) 1800 501 366 • Facsimile (NZ) +64 9 488 8787 or (Aust) +61 3 9473 2500 Please assist our registrar by quoting your CSN or shareholder number. 7 1 0 O B E m o c . t h g i s n i y b d e n g i s e d EBOS Annual Report 2014 | 55 www.ebosgroup.com